

## Design, Synthesis, and Preclinical Evaluations of Novel 4-Substituted 1,5-Diarylanilines as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Drug Candidates

Lian-Qi Sun, Lei Zhu, Keduo Qian, Bingjie Qin, Li Huang, Chin-Ho Chen, Kuo-Hsiung Lee, and Lan Xie

*J. Med. Chem.*, **Just Accepted Manuscript** • DOI: 10.1021/jm3007678 • Publication Date (Web): 02 Aug 2012

Downloaded from <http://pubs.acs.org> on August 3, 2012

### Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



1  
2  
3  
4  
5  
6  
7 **Design, Synthesis, and Preclinical Evaluations of Novel**  
8  
9  
10 **4-Substituted 1,5-Diarylanilines as Potent HIV-1**  
11  
12 **Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)**  
13  
14  
15 **Drug Candidates**  
16  
17  
18  
19  
20

21 Lian-Qi Sun,<sup>†</sup> Lei Zhu,<sup>‡</sup> Keduo Qian,<sup>||</sup> Bingjie Qin,<sup>†</sup> Li Huang,<sup>‡</sup>  
22  
23  
24 Chin Ho Chen,<sup>‡</sup> Kuo-Hsiung Lee<sup>||,⊥</sup> and Lan Xie<sup>†\*</sup>  
25  
26  
27  
28  
29  
30

31 <sup>†</sup>*Beijing Institute of Pharmacology & Toxicology, 27 Tai-Ping Road, Beijing, 100850,*  
32  
33  
34 *China*  
35

36 <sup>‡</sup>*Duke University Medical Center, Box 2926, Surgical Oncology Research Facility,*  
37  
38  
39 *Durham, NC 27710, USA*  
40

41 <sup>||</sup>*Natural Products Research Laboratories, UNC Eshelman School of Pharmacy,*  
42  
43  
44 *University of North Carolina, Chapel Hill, NC 27599-7568, USA*  
45

46 <sup>⊥</sup>*Chinese Medicine Research and Development Center, China Medical University and*  
47  
48 *Hospital, Taichung, Taiwan*  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract**

Twenty-one new 4-substituted diarylaniline compounds (DAANs) (Scheme 2, series **13**, **14**, and **15**) were designed, synthesized, and evaluated against wild-type and drug resistant HIV-1 viral strains. As a result, approximately a dozen new DAANs showed high potency with low nano- to sub-nanomolar EC<sub>50</sub> values ranging from 0.2 to 10 nM. The three most promising compounds **14e**, **14h**, and **15h** exhibited high potency against wild-type and drug-resistant viral strains with EC<sub>50</sub> values at the sub-nanomolar level (0.29-0.87 nM), and were comparable to or more potent than the new NNRTI drug riplivirine (**2**) in the same assays. Drug-like physicochemical property assessments revealed that the most active DAANs (EC<sub>50</sub> <10 nM) have better aqueous solubility (>1-90 µg/mL at pH 7.4 and pH 2) and metabolic stability in vitro than **2**, as well as desirable log P values (<5) and polar surface area (PSA) (<140 Å<sup>2</sup>). These promising results warrant further development of this novel compound class as potential potent anti-AIDS clinical trial candidates.

## INTRODUCTION

Since the first case of acquired immunodeficiency syndrome (AIDS) was reported by the U. S. in 1981, the scientific progress in HIV/AIDS research has been extraordinary, especially in the development of antiretroviral therapy (ART) that has proven to be life-saving to millions of people. Recent scientific evidence has demonstrated that ART is also effective at preventing infection,<sup>1,2</sup> thus offering an unprecedented opportunity to control the AIDS pandemic. Therefore, the discovery and development of novel highly potent anti-HIV drugs remains imperative. Among current anti-HIV drugs, non-nucleoside reverse transcriptase inhibitors (NNRTIs) are used in combination as key components in the highly active antiretroviral therapy (HAART).<sup>3,4</sup> Currently, five NNRTI drugs have been approved by the US FDA for AIDS therapy, including three first-generation compounds, nevirapine, delavirdine, and efavirenz, and two second-generation compounds, etravirine (**1**)<sup>5</sup> and rilpivirine (**2**)<sup>6</sup> (Figure 1). NNRTI drugs have the advantages of high potency and low toxicity, but rapid viral drug-resistance to the first-generation NNRTI drugs has limited their clinical uses. Fortunately, the new NNRTI drugs **1** and **2** overcome the deficiency of early NNRTI drugs. Both **1** and **2** possess extremely potent antiviral activity with low nano- or sub-nanomolar EC<sub>50</sub> values against wild-type and a broad spectrum of mutated NNRTI resistant strains. There is also a higher genetic barrier for HIV-1 to evolve resistance to the two new NNRTIs.<sup>7,8</sup> Drugs **1** and **2** belong to the same structural family, diarylpyrimidines (DAPYs). Rilpivirine is three-fold more potent than etravirine and is used in a low oral dose (25 mg/tablet) once-daily. These successes greatly encourage continuing research to discover and develop additional novel next-generation NNRTI drugs with diverse molecular scaffolds for more efficacious therapy and potential AIDS prevention.

1  
2  
3 During our prior studies,<sup>9,10</sup> we discovered a series of diarylaniline (DAAN)  
4  
5 compounds with low nanomolar anti-HIV potency against wild-type and HIV-1  
6  
7 RT-resistant viral strains, as well as a new chemo-type scaffold and simplified synthesis.  
8  
9 As an example, lead **3** (Figure 1) exhibited sub-nanomolar EC<sub>50</sub> values against wild-type  
10  
11 (EC<sub>50</sub> 0.63 nM) and RT multi-resistant (0.9 nM) viral strains, which were comparable to  
12  
13 those of rilpivirine (0.52 nM and 0.49 nM, respectively) in the same assays. However,  
14  
15 further physical chemistry studies revealed that **3** possessed poor aqueous solubility  
16  
17 (0.29 µg/mL) and low permeability ( $P_{\text{app}} < 2 \times 10^{-6}$  cm/s) in a Caco-2 assay, which  
18  
19 might limit molecular absorption and cause low oral bioavailability in vivo. Therefore,  
20  
21 further lead optimization of DAANs is necessary to surmount these deficiencies.  
22  
23  
24

25  
26 Our further optimization strategy is shown in Figure 2. Based on prior SAR  
27  
28 results, the two known pharmacophores of DAANs, the *para*-cyanoaniline moiety  
29  
30 (A-ring) and the crucial amino group (NH<sub>2</sub>) on the central phenyl ring (B-ring) *ortho* to  
31  
32 the NH group linking the B and A rings were maintained. With regard to the structural  
33  
34 difference between drugs **1** and **2**,<sup>11</sup> one modifiable point appeared to be the  
35  
36 *para*-substituent (R<sup>2</sup>) on the trisubstituted phenoxy ring (C-ring). We postulated that a  
37  
38 hydrophobic, flexible, and more linear substituent at this position might insert into the  
39  
40 narrow tunnel on the NNRTI binding site and interact with the reserved W229 to  
41  
42 enhance antiviral potency against wild-type and resistant viral strains. While early  
43  
44 molecular modeling results on DAANs supported the importance of the NH<sub>2</sub> on the  
45  
46 central phenyl (ring B) for high anti-HIV activity, the results also revealed that the nitro  
47  
48 group (R<sup>1</sup>) opposite the amino group on the central phenyl ring (B-ring) created a small  
49  
50 electrostatic interaction with the positively charged amino acid K172 on the NNRTI  
51  
52 binding site.<sup>9</sup> Thus, R<sup>1</sup> presents another opportunistic position that we hypothesized  
53  
54 could lead to improvement in molecular physicochemical properties and related  
55  
56  
57  
58  
59  
60

1  
2  
3 drug-like properties without loss of anti-HIV potency. Accordingly, a series of new  
4  
5 DAAN analogues with different  $R^1$  substituents on the B-ring, either ionizable, polar  
6  
7 groups or H-bond donors and acceptors, were synthesized and evaluated. Herein, we  
8  
9 report the synthesis, anti-HIV activity, physicochemical properties, and some drug-like  
10  
11 properties *in vitro* of new 4-substituted 1,5-diarylaniline analogues (DAANs). Their  
12  
13 structure-activity relationship (SAR) and structure-property relationship (SPR)  
14  
15 correlations are also discussed.  
16  
17  
18  
19  
20




Figure 1. Next-generation NNRTI drugs and DAAN lead 3.





Figure 2. Leads DAANs, known SAR, and further optimization strategy

**Chemistry.** We designed a short synthetic route (see Schemes 1 and 2) that would allow the rapid and simultaneous optimization of the two variable points (i.e.,  $R^1$


1  
2  
3 and R<sup>2</sup>) to produce three (**13**, **14**, **15**) new series of DAAN compounds. Our approach  
4  
5 was to first prepare building blocks **7–9** (Scheme 1). 2,4-Dichloro-5-trifloromethyl-  
6  
7 nitrobenzene (**4**) is commercially available. 2,4-dichloro-5-nitrobenzenesulfonamide (**5**)  
8  
9 was prepared from 2,4-dichloronitrobenzene by treatment with chlorosulfuric acid,  
10  
11 followed by addition of ammonia hydroxide solution. Nitration of 2,4-dichlorobenzoic  
12  
13 acid with concentrated HNO<sub>3</sub> and H<sub>2</sub>SO<sub>4</sub>, followed by esterification with methanol in  
14  
15 the presence of H<sub>2</sub>SO<sub>4</sub> produced methyl 2,4-dichloro-5- nitrobenzoate (**6**). Subsequently,  
16  
17 coupling of **4**, **5**, or **6** with 4-cyanoaniline in DMF in the presence of excess cesium  
18  
19 carbonate provided the corresponding intermediate 4-substituted 5-chloro-*N*-(4-  
20  
21 -cyanophenyl)-2- nitroanilines **7–9**, respectively. Consistent with our previous results,  
22  
23 the 4-cyanoaniline moiety preferred to attack the chloride at the *ortho*-position to the  
24  
25 nitro group.<sup>9</sup> The <sup>1</sup>H NMR signals of the linker NH in **7–9** were shifted down-field to δ  
26  
27 9.76–9.84 ppm due to a neighboring chelating effect with the adjacent nitro group.  
28  
29

30  
31  
32 As shown in Scheme 2, intermediates **7–9** were subsequently coupled with  
33  
34 4-substituted 3,5-dimethylphenols in DMF in the presence of potassium carbonate,  
35  
36 either under microwave irradiation at 190 °C for 10–15 min or by traditional heating at  
37  
38 130 °C for 5 h, to afford corresponding 2,4-diarylnitrobenzene compounds **10a–c** and  
39  
40 **11c–d** with the required three-phenyl ring scaffold. Furthermore, Aldol condensation of  
41  
42 **10a** with acetone generated compound **11a**. Wittig-Honer reaction of aldehyde **10a–10c**  
43  
44 with diethyl cyanomethyl phosphonate generated corresponding cyanovinyl compounds  
45  
46 **12a–12c**. Compound **12c** was hydrolyzed under basic condition to yield acid **12d**.  
47  
48 Compound **12d** was treated with thionyl chloride and the resulting acid chloride was  
49  
50 treated with: (i) ammonia or (ii) methylamine or (iii) hydrazine to generate  
51  
52 corresponding compounds **12e** or **12f** or **12g** respectively. The reduction of the ester  
53  
54 group in **10c** and **12c** with lithium borohydride (LiBH<sub>4</sub>) produced hydroxymethyl  
55  
56  
57  
58  
59  
60

1  
2  
3 compounds **11e** and **12h**, respectively. The preparation of intermediate **12i** was reported  
4  
5 previously.<sup>10</sup> Finally, the nitro group on the central ring in **11a** and **12** was treated with  
6  
7 the mild reducing reagent sodium hydrosulfite to produce corresponding target DAAN  
8  
9 compounds **13a** and series **14 (a-f, h)**. Catalytic hydrogenation of **12** with hydrogen  
10  
11 (30-40 p.s.i.) in the presence of Pd/C (5-10%) in anhydrous ethanol afforded the new  
12  
13 series **15** DAAN compounds, in which the nitro group on the central ring and the double  
14  
15 bond of the *para*-cyanovinyl group on the phenoxy moiety (C-ring) were reduced. By  
16  
17 using the same catalytic hydrogenation, 5-substituted 2,4-diaryl-nitrobenzenes **11a** and  
18  
19 **11c-e** were converted target series **13 (b-e)**. To confirm the importance of the NH<sub>2</sub> on the  
20  
21 B-ring for anti-HIV activity, 1,6-diaryl-benzoimidazole compounds **16a** and **16b** were  
22  
23 prepared by cyclization of **14f** and **15f**, respectively, with triethyl orthoformate.<sup>12</sup> The  
24  
25 successful synthesis of **16a** and **16b** further validated the structures of intermediates **7-9**  
26  
27 as shown and described above.  
28  
29  
30  
31  
32  
33



**Scheme 1** a) ClSO<sub>3</sub>H, 0–140 °C; b) NH<sub>4</sub>OH/THF, 0 °C, 0.5 h; c) HNO<sub>3</sub>/H<sub>2</sub>SO<sub>4</sub>, 2h; d) H<sub>2</sub>SO<sub>4</sub>/MeOH, reflux, 2 h; e) *t*-BuOK/DMF, r.t. 1 h.



**Scheme 2.** a) K<sub>2</sub>CO<sub>3</sub>/DMF, 190 °C, MW, 15 min or traditional heating at 130 °C, 5 h; b) (EtO)<sub>2</sub>P(O)CH<sub>2</sub>CN, *t*-BuOK/THF, 0 °C – r.t., 3 h; c) aq NaOH/THF/MeOH, r.t., 4 h; d) (i) SOCl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub>, reflux, 3 h; (ii) NH<sub>4</sub>OH/THF, 0 °C, 0.5 h; e) (i) SOCl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub>, reflux, 3 h; (ii) NH<sub>2</sub>CH<sub>3</sub> in THF, 0 °C, 0.5 h; f) (i) SOCl<sub>2</sub>/CH<sub>2</sub>Cl<sub>2</sub>, reflux, 3 h; (ii) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O, r.t., 1 h; g) CH<sub>3</sub>COCH<sub>3</sub>, MeOH/aq NaOH (10%), 0 °C – rt, 1 h; h) LiBH<sub>4</sub>, THF/MeOH, 1 h; i) Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>/NH<sub>4</sub>OH, THF/H<sub>2</sub>O (v/v 1:1), r.t.; j) H<sub>2</sub>/Pd-C, EtOH, 2-4 h; k) CH(OEt)<sub>3</sub>, HCl (1N), C<sub>2</sub>H<sub>5</sub>OC<sub>2</sub>H<sub>5</sub>/DMF, r.t. 3 h.

## RESULTS AND DISCUSSION

Initially, we evaluated the 4-trifluoromethyl DAAN compounds (**13a-d**, **14a**, and **15a**) in which the nitro group ( $R^1$ ) on the B-ring of lead **3** had been replaced with a strong electron-withdrawing trifluoromethyl group, and various *para*-substituents ( $R^2$ ) were present on the C-ring. All six compounds exhibited high potency against wild-type HIV-1 replication with low nanomolar  $EC_{50}$  values ranging from 1.3 to 13.8 nM and selective indexes (SI) between 789 and 6454 (Table 1). These results showed that the  $R^1$  substituent on the central phenyl ring could be modified without losing high anti-HIV activity. However, the introduced trifluoromethyl group resulted in log P values greater than 5 and did not improve aqueous solubility ( $< 1 \mu\text{g/mL}$ ) over a broad pH range (2.0-7.4) (Table 1). Consequently,  $R^1$  on the B-ring was changed to other substituents in an attempt to achieve potential drug candidates with more desirable drug-like properties and high anti-HIV potency. Newly synthesized series **14** and **15** DAANs with various  $R^1$  groups on the B-ring and either a *para*-cyanovinyl or *para*-cyanoethyl  $R^2$  group, respectively, on the C-ring were evaluated against wild-type HIV-1 replication. Except for **14b**, **15b**, **14d**, and **15d**, the compounds in these two series exhibited very high antiviral potency with low to sub-nanomolar  $EC_{50}$  values (0.39–10 nM). Among them, the two most potent compounds **14h** and **15h**, with a 4-hydroxymethyl group ( $R^1$ ), exhibited sub-nanomolar  $EC_{50}$  values of 0.53 nM and 0.39 nM, respectively, which were comparable with or slight better than that of **2** in the same assay. Three other pairs of analogues, **14c** and **15c** with a 4-ester ( $\text{COOCH}_3$ ), **14e** and **15e** with 4-amide ( $\text{CONH}_2$ ), and **14f** and **15f** with 4-methylamide ( $\text{CONHCH}_3$ ), also displayed high potency with low

1  
2  
3  
4 nanomolar EC<sub>50</sub> values ranging from 0.87 to 5.72 nM, regardless of whether R<sup>2</sup> on the  
5  
6 C-ring was *para*-cyanovinyl (**14**) or *para*-cyanoethyl (**15**). In contrast, the presence of  
7  
8 4-sulfamoyl (SO<sub>2</sub>NH<sub>2</sub>, **14b** & **15b**) or 4-carboxylic acid (COOH, **14d** & **15d**) on the  
9  
10 B-ring resulted in substantially reduced antiviral activity (EC<sub>50</sub> 94-380 nM), suggesting  
11  
12 that a very polar substituent at the 4-position might impede the interaction between the  
13  
14 inhibitor(s) and the NNRTI binding site. In a comparison of 4-amide-DAAN **15e**,  
15  
16 4-amino-DAAN **15i**, and 4-hydrazine-DAAN **15g**, compound **15e** (EC<sub>50</sub> 1.39 nM) was 5  
17  
18 and 13-fold more potent than **15i** (7.30 nM) and **15g** (EC<sub>50</sub> 19.1), respectively, indicating  
19  
20 that the distance between the amino group in the R<sup>1</sup> substituent and the central phenyl  
21  
22 ring might influence the antiviral activity. Therefore, we postulated that an  
23  
24 electron-withdrawing R<sup>1</sup> group with appropriate volume and length on the B-ring might  
25  
26 be necessary to provide additional interaction(s) within the NNRTI binding pocket for  
27  
28 maintaining or enhancing antiviral potency. However, when the two neighboring amino  
29  
30 groups on the central phenyl ring of the active compound **14f** and **15f** were cyclized,  
31  
32 both products **16a** and **16b** lost antiviral potency (EC<sub>50</sub> > 220 nM). This result supported  
33  
34 our previous hypothesis that an amino group on the central B-ring *ortho* to the  
35  
36 aniline moiety is crucial for achieving high potency. Finally, DAAN **13e**, with two  
37  
38 hydroxymethyl groups (R<sup>1</sup> and R<sup>2</sup>), exhibited 20-fold lower activity (EC<sub>50</sub> 10.0 nM) than  
39  
40 the most active compounds **14h** and **15h**, in which R<sup>2</sup> was *para*-cyanovinyl or  
41  
42 *para*-cyanoethyl, respectively. This finding is consistent with our previous SAR  
43  
44 results,<sup>10</sup> that a hydrophobic and linear *para*-R<sup>2</sup> on the C-ring is favored for antiviral  
45  
46 activity.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Considering them to be next-generation NNRTIs, we chose new DAANs with  
5  
6 EC<sub>50</sub> values less than 5 nM to test against three NNRTI resistant HIV-1 mutants  
7  
8 RT-multi-drug-resistant (MRTDR), K101E, and E138K. It is reported that K101E and  
9  
10 E138K are two of the mutations that confer resistance to new drugs **1** and **2**.<sup>13</sup>  
11  
12 Interestingly, the newly synthesized active DAANs exhibited potent activity against the  
13  
14 drug resistant viral strains with low nanomolar EC<sub>50</sub> values. The most active compounds  
15  
16 **14h** and **15h** were slightly more potent than **2** and three- to four-fold more potent than **3**  
17  
18 against these mutated viral strains, with the notable exception that **15h** was now more  
19  
20 resistant against the RTMDR strain.  
21  
22  
23  
24

25  
26 To evaluate their potential as drug candidates, five pairs of new active DAANs  
27  
28 (EC<sub>50</sub> < 10 nM) were further assessed for their physicochemical and drug-like properties  
29  
30 as shown in Table 4. We first measured their aqueous solubility by using an HPLC/UV  
31  
32 method, in parallel with **2** and **3**. All tested DAANs, except **14a** and **15a**, showed  
33  
34 improved solubility at both pH 7.4 and pH 2.0 compared with **3**, and were generally  
35  
36 more soluble in acidic than neutral conditions, because of the presence of a free amine  
37  
38 group. Notably, the most active compound **15h** had aqueous solubility of 89.8 µg/mL at  
39  
40 pH 2.0 and 18.8 µg/mL at pH 7.4, comparable to and better than **2** (86 µg/mL at pH 2.0  
41  
42 and 0.24 µg/mL at pH 7.4) in the same assay (lit. 20 ng/mL at pH 7.0).<sup>14</sup> In addition,  
43  
44 **15c**, **15f**, **14h**, and **13e** also showed moderate solubility ranging from 20.9-44.7 µg/mL  
45  
46 under acidic conditions, which would enhance molecular absorbability in the stomach. A  
47  
48 comparison of the **14** and **15** series showed that the **15** series compounds were generally  
49  
50 more soluble than the corresponding **14** series compounds, suggesting that the greater  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


1  
2  
3 flexibility of the cyanoethyl group ( $R^2$ ) on the C-ring might contribute to better aqueous  
4  
5 solubility. Additionally, **15** series compounds had slightly or significantly lower melting  
6  
7 points than corresponding **14** series compounds. Next, we assessed the lipophilicity of  
8  
9 the active DAANs by measuring their octanol/water (aqueous buffer pH 7.4) partition  
10  
11 coefficients by an HPLC/UV method. The log P values of **14c/15c**, **14e/15e**, **14f/15f**,  
12  
13 and **14h/15h** ranged from 2.65–4.15 and, consistent with aqueous solubility, were also  
14  
15 improved compared with **14c/15c**, **2**, and **3**. The pattern was also similar to the predicted  
16  
17 clog D values. Subsequently, molecular PSA (polar surface area) values were calculated  
18  
19 by using DS software (3.0) as a prediction of oral bioavailability. The values for all  
20  
21 compounds fell in a desirable range of 88.13-138 (a criterion  $<140 \text{ \AA}^2$ ).<sup>15</sup> Furthermore,  
22  
23 metabolic stability of these active DAANs was evaluated by a human liver microsome  
24  
25 incubation assay, in parallel with **2**. Most of the active DAANs displayed better stability  
26  
27 than **2** ( $t_{1/2}$  34.2 min); however, the most potent 4-hydroxymethyl DAANs **14h** and **15h**  
28  
29 appeared to be less stable ( $t_{1/2}$  30.2 and 20.9 min, respectively) and had higher clearance  
30  
31 (CL 0.23 and 0.33, respectively) than **2** and others in the same assay.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

## 43 CONCLUSION

44  
45 Based on our current optimization strategy, 21 new DAAN analogues (series **13**, **14**, and  
46  
47 **15**) were synthesized by modifying  $R^1$  on the central phenyl ring (B-ring) and  $R^2$  on the  
48  
49 phenoxy ring (C-ring). Seventeen of the new target compounds showed significant  
50  
51 anti-HIV activity ( $EC_{50} < 20 \text{ nM}$ ). The most promising compounds **14e**, **14h**, and **15h**  
52  
53 exhibited high potency against wild-type and drug-resistant viral strains with  $EC_{50}$   
54  
55 values at a subnanomolar level (0.29-0.87 nM), and were comparable or more potent  
56  
57  
58  
59  
60


1  
2  
3 than new NNRTI drug **2** in the same assays. The modifications of the R<sup>1</sup> substituent on  
4  
5 the central B-ring provided the following new structure-activity relationship (SAR)  
6  
7 correlations for DAANs: (1) R<sup>1</sup> is modifiable to improve molecular drug-like properties  
8  
9 without loss of potency. (2) R<sup>1</sup> as H-bond donor and/or acceptor is favorable for  
10  
11 anti-HIV potency and drug-like properties, and (3) the presence of a too polar R<sup>1</sup>, such  
12  
13 as COOH or SO<sub>2</sub>NH<sub>2</sub>, greatly decreases potency. In addition, current results also  
14  
15 supported our previous SAR: (1) a favorable R<sup>2</sup> substituent on the C-ring should be  
16  
17 hydrophobic, flexible and more linear, such as either a *para*-cyanovinyl or  
18  
19 *para*-cyanoethyl; (2) the amino (NH<sub>2</sub>) group on the central ring is crucial for achieving  
20  
21 high potency (see **16a** and **16b**). The assessment of drug-like physicochemical properties  
22  
23 for four pairs of active DAANs (EC<sub>50</sub> < 6 nM) indicated that introducing a suitable R<sup>1</sup>  
24  
25 on the central phenyl ring can indeed improve molecular physicochemical properties,  
26  
27 such as aqueous solubility, log P values, PSA, and metabolic stability, which will benefit  
28  
29 drug ADME properties. The current results hold great promise for the identification of  
30  
31 potential new drug candidates with high potency and desirable drug-like properties.  
32  
33 Further studies on pharmacokinetic properties in vivo are ongoing and will be reported  
34  
35 later.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1.** Structures, antiviral activity, and physicochemical properties of 4-trifluoromethyl diarylanilines **13a-d**, **14a**, and **15a**



	R <sup>2</sup>	NL4-3 (wt) in TZM-bl cells			Aqueous solubility		Log P
		EC <sub>50</sub> (nM) <sup>a</sup>	CC <sub>50</sub> (μM) <sup>b</sup>	SI <sup>c</sup>	pH 7.4	pH 2.0	
<b>13a</b>	CH=CHCOCH <sub>3</sub>	10.9 ± 2.58	>8.6	>789	--	--	--
<b>13b</b>	CH <sub>2</sub> CH <sub>2</sub> COCH <sub>3</sub>	6.85 ± 1.73	11.1	1620	0.16	0.28	>5
<b>13c</b>	CN	3.79 ± 0.83	13.3	3509	0.26	0.96	>5
<b>13d</b>	NH <sub>2</sub>	13.8 ± 4.37	15.8	1145	--	--	--
<b>14a</b>	CH=CHCN	9.38 ± 2.45	15.0	1599	0.24	0.42	>5
<b>15a</b>	CH <sub>2</sub> CH <sub>2</sub> CN	1.13 ± 0.31	> 7.1	> 6454	0.24	0.33	>5
<b>3</b>		0.63 ± 0.13	>24.4	>38730	0.29	0.29	>5
<b>2</b>		0.52 ± 0.14	19.4	37305			


<sup>a</sup> Concentration of compound that causes 50% inhibition of viral replication, presented as mean ± standard deviation (SD), performed at least in triplicate. <sup>b</sup> XTT assay was used to determine the CC<sub>50</sub> value that causes cytotoxicity to 50% cells. <sup>c</sup> SI (Selectivity index) is the ratio of CC<sub>50</sub>/EC<sub>50</sub>.

**Table 2.** Structures and antiviral activity of diarylanilines **14-16** and **13e**<sup>a</sup>

	R <sup>1</sup>	R <sup>2</sup>	NL4-3 (wt)		
			EC <sub>50</sub> (nM) <sup>b</sup>	CC <sub>50</sub> (μM) <sup>c</sup>	SI <sup>d</sup>
<b>14b</b>	SO <sub>2</sub> NH <sub>2</sub>	CH=CHCN	93.7 ± 24.0	>21.8	>233
<b>15b</b>	SO <sub>2</sub> NH <sub>2</sub>	CH <sub>2</sub> CH <sub>2</sub> CN	380 ± 67	11.1	29.2
<b>14c</b>	COOCH <sub>3</sub>	CH=CHCN	2.74 ± 0.71	>22.8	>8321
<b>15c</b>	COOCH <sub>3</sub>	CH <sub>2</sub> CH <sub>2</sub> CN	4.32 ± 1.54	>22.7	>5255
<b>14d</b>	COOH	CH=CHCN	230 ± 38	14.9	65
<b>15d</b>	COOH	CH <sub>2</sub> CH <sub>2</sub> CN	96.0 ± 21	14.3	149
<b>14e</b>	CONH <sub>2</sub>	CH=CHCN	0.87 ± 0.28	>23.6	>27126
<b>15e</b>	CONH <sub>2</sub>	CH <sub>2</sub> CH <sub>2</sub> CN	1.39 ± 0.33	>9.4	>6762
<b>14f</b>	CONHCH <sub>3</sub>	CH=CHCN	5.72 ± 0.94	>9.2	>1608
<b>15f</b>	CONHCH <sub>3</sub>	CH <sub>2</sub> CH <sub>2</sub> CN	2.73 ± 0.41	>9.1	>3330
<b>15g</b>	CONHNH <sub>2</sub>	CH <sub>2</sub> CH <sub>2</sub> CN	19.1 ± 5.68	>22.7	>1188
<b>14h</b>	CH <sub>2</sub> OH	CH=CHCN	0.53 ± 0.13	16.3	30755
<b>15h</b>	CH <sub>2</sub> OH	CH <sub>2</sub> CH <sub>2</sub> CN	0.39 ± 0.11	>23.8	61026
<b>15i</b>	NH <sub>2</sub>	CH <sub>2</sub> CH <sub>2</sub> CN	7.30 ± 1.26	>25	>3906
<b>13e</b>	CH <sub>2</sub> OH	CH <sub>2</sub> OH	10.0 ± 2.06	15.9	1590
<b>16a</b>	CONHCH <sub>3</sub>	CH=CHCN	>220	>890	—
<b>16b</b>	CONHCH <sub>3</sub>	CH <sub>2</sub> CH <sub>2</sub> CN	>220	>890	—
<b>3</b>	NO <sub>2</sub>	CH=CHCN	0.63 ± 0.13	>24.4	>38730
<b>2</b>			0.52 ± 0.14	19.4	37305

<sup>a</sup> Against HIV-1 NL3-4 (wild-type) virus in TZM-bl cell lines. <sup>b</sup> Concentration of compound that causes 50% inhibition of viral replication, presented as mean ± standard deviation (SD), and performed at least in triplicate. <sup>c</sup> XTT assay was used to determine the CC<sub>50</sub> value that causes cytotoxicity to 50% cells. <sup>d</sup> SI (Selectivity index) is the ratio of CC<sub>50</sub>/EC<sub>50</sub>.

**Table 3.** Antiviral activity against wild-type and mutated viral strains of selected active DAANs



	R <sup>1</sup>	R <sup>2</sup>	EC <sub>50</sub> (nM) <sup>a</sup> (Fold Change) <sup>b</sup>			
			NL4-3	RTMDR <sup>c</sup>	K101E <sup>d</sup>	E138K <sup>d</sup>
<b>14e</b>	CONH <sub>2</sub>	CH=CHCN	0.87	1.8 ± 0.5 (2.1)	8.3 ± 3.3 (9.5)	9.0 ± 2.6 (10.3)
<b>14h</b>	CH <sub>2</sub> OH	CH=CHCN	0.53	0.4 ± 0.1 (0.7)	3.4 ± 1.0 (6.4)	3.9 ± 0.9 (7.4)
<b>15c</b>	COOCH <sub>3</sub>	CH <sub>2</sub> CH <sub>2</sub> CN	4.32	4.1 ± 0.7 (0.9)	14 ± 4.3 (3.2)	7.5 ± 2.7 (1.7)
<b>15f</b>	CONHCH <sub>3</sub>	CH <sub>2</sub> CH <sub>2</sub> CN	2.73	8.0 ± 4.3 (2.9)	14 ± 4.8 (5.1)	10 ± 3.9 (3.7)
<b>15h</b>	CH <sub>2</sub> OH	CH <sub>2</sub> CH <sub>2</sub> CN	0.39	1.8 ± 0.5 (4.6)	3.4 ± 1.3 (8.7)	2.9 ± 1.2 (7.4)
<b>3</b>	NO <sub>2</sub>	CH=CHCN	0.63	0.9 ± 0.3 (1.4)	11 ± 3.6 (17.5)	12 ± 3.9 (19.0)
<b>2</b>			0.52	0.5 ± 0.1 (0.9)	5.7 ± 1.4(11.0)	5.2 ± 1.6 (10.0)

<sup>a</sup> Experiments performed at least in triplicate and data presented as means ± SD. <sup>b</sup>


resistant fold change. <sup>c</sup> HIV-1 RTMDR (obtained from AIDS Research and Reference

Reagent Program, Division of AIDS, NIAID, NIH), which contains mutations in RT

amino acid residues L74, M41L, V106A, and T215Y, is resistant to AZT, ddI, nevirapine,

and other nonnucleoside RT inhibitors. <sup>d</sup> mutated amino acids in the HIV-RT

non-nucleoside binding pocket (NNBP) confer resistance to **2**.

**Table 4.** Structures and drug-like properties of active DAANs **14** and **15** ( $EC_{50} < 10$  nM)**14**  $R^2 = -CH=CHCN$ , **15**  $R^2 = -CH_2CH_2CN$ 

	$R^1$	$EC_{50}$ (nM)	Aqueous solubility ( $\mu\text{g/mL}$ ) <sup>a</sup>		Mp °C	logP <sup>a</sup>	clogD <sup>b</sup>	PSA <sup>b</sup>	HLM <sup>c</sup>	
			pH 2.0	pH 7.4					$t_{1/2}$ min	CL mL/min/mg
<b>14a</b>	CF <sub>3</sub>	9.38	0.42	0.24	224-6	>5	7.09	94.86	45.0	0.15
<b>15a</b>	CF <sub>3</sub>	1.13	0.33	0.24	172-4	>5	6.49	94.86	55.7	0.12
<b>14c</b>	CO <sub>2</sub> CH <sub>3</sub>	2.74	1.75	1.30	240-2	4.15	5.06	121.16	283	0.02
<b>15c</b>	CO <sub>2</sub> CH <sub>3</sub>	4.32	21.8	1.21	236-8	4.15	4.46	121.16	186	0.04
<b>14e</b>	CONH <sub>2</sub>	0.87	2.09	0.63	290-2	3.53	4.38	137.94	35.0	0.20
<b>15e</b>	CONH <sub>2</sub>	1.39	9.11	0.06	274-6	2.65	3.79	137.94	42.0	0.16
<b>14f</b>	CONHCH <sub>3</sub>	5.72	8.63	1.32	112-4	4.12	3.93	123.96	44.8	0.15
<b>15f</b>	CONHCH <sub>3</sub>	2.73	44.7	8.28	110-2	2.65	3.33	123.96	55.7	0.12
<b>14h</b>	CH <sub>2</sub> OH	0.53	20.9	3.23	186-8	4.14	3.55	115.09	30.2	0.23
<b>15h</b>	CH <sub>2</sub> OH	0.39	89.8	18.8	115-7	3.68	2.95	115.09	20.9	0.33
<b>3</b>	NO <sub>2</sub>	0.63	0.29	0.29	252-4	>5	5.88	140.67	47.8	0.15
<b>2</b>		0.52	86.8	0.24 <sup>d</sup>	246-8	>5	3.62	97.41	34.2	0.20

<sup>a</sup> Measured at pH 7.4 in triplicate. A general solubility guideline for human oral absorption is <10  $\mu\text{g/mL}$  low; 10-60  $\mu\text{g/mL}$  moderate, >60  $\mu\text{g/mL}$  high.<sup>16</sup>

<sup>b</sup> Predicted by using software ACD or DS 3.0, respectively. <sup>c</sup> Human liver microsome incubation assay, data from at least two experiments in parallel. <sup>d</sup> 20 ng/mL at pH 7.0 reported in reference 14.

## EXPERIMENTAL SECTION

**Chemistry.** Melting points were measured with an RY-1 melting apparatus without correction. The proton nuclear magnetic resonance ( $^1\text{H}$  NMR) spectra were measured on a JNM-ECA-400 (400 MHz) spectrometer using tetramethylsilane (TMS) as the internal standard. The solvent used was  $\text{CDCl}_3$  unless otherwise indicated. Mass spectra were measured on an ABI Perkin-Elmer Sciex API-150 mass spectrometer with electrospray ionization, and the relative intensity of each ion peak is presented as percent (%). The purities of target compounds were  $\geq 95\%$ , measured by HPLC analyses, which were performed on an Agilent 1100 HPLC system with a UV detector and a Grace Alltima HP C18 column ( $100 \times 2.1$  mm,  $3 \mu\text{m}$ ) eluting with a mixture of solvents A and B (condition 1: acetonitrile/water 70:30, flow rate 1.0 mL/min; condition 2: MeOH/water 70:30, flow rate 0.8 mL/min; UV 254 nm). The microwave reactions were performed on a microwave reactor from Biotage, Inc. Thin-layer chromatography (TLC) and preparative TLC plates used silica gel GF254 (200-300 mesh) purchased from Qingdao Haiyang Chemical Company. Medium-pressure column chromatography was performed using a CombiFlash companion purification system. All chemical reagents and solvents were obtained from Beijing Chemical Works or Sigma-Aldrich, Inc. NADPH,  $\text{MgCl}_2$ ,  $\text{KH}_2\text{PO}_4$ ,  $\text{K}_2\text{HPO}_4$  and reference compound propranolol were purchased from Sigma-Aldrich. HPLC-grade acetonitrile for LC-MS analysis was purchased from VWR. Pooled human liver microsomes (Lot No# 28831) were purchased from BD biosciences (Woburn, MA).

**2,4-Dichloro-5-nitrobenzene-1-sulfonyl Chloride.** Chlorosulfonic acid (30 mL) cooled to  $0^\circ\text{C}$  was added dropwise into 2,4-dichloro-nitrobenzene (9.6 g, 50 mmol) with stirring. Then the solution was allowed to warm to rt, followed by heating at  $140^\circ\text{C}$  for 2 h. After cooling to rt, ice-water was added dropwise to the mixture. A solid

1  
2  
3 precipitated, and was filtered and washed with cold water. The collected crude product  
4  
5 was re-crystallized from EtOAc to give 10.6 g of pure sulfonyl chloride in 73% yield,  
6  
7 white solid, mp 116-118 °C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ ppm 7.95 (1H, s, ArH-3), 8.44 (1H,  
8  
9 s, ArH-5).

10  
11 **2,4-Dichloro-5-nitrobenzenesulfonamide (5).** A solution of the above  
12  
13 sulfonyl chloride (290 mg, 1 mmol) in THF was added to aqueous ammonia solution  
14  
15 (25%, 1 mL, excess) at 0 °C (ice-bath) and stirred at the same temperature for an  
16  
17 additional 0.5 h. The mixture was then poured into ice-water and let stand overnight.  
18  
19 The precipitated white solid was filtered and washed with cold water to provide 207 mg  
20  
21 of **5**, 77% yield, white powder, mp 176-178 °C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ ppm 8.02 (2H, s,  
22  
23 SO<sub>2</sub>NH<sub>2</sub>), 8.27 (1H, s, ArH-3), 8.58 (1H, s, ArH-5).

24  
25 **2, 4-Dichloro-5-nitrobenzoic Acid.** 2, 4-Dichlorobenzoic acid (191 mg, 1  
26  
27 mmol) was dissolved completely in H<sub>2</sub>SO<sub>4</sub> (98%, 5 mL) with a mechanical stirrer at  
28  
29 0 °C. Then the solution was added dropwise to HNO<sub>3</sub> (con., 0.5 mL) with stirring, and  
30  
31 the temperature was kept below 5 °C. The mixture was stirred at rt for 2 h with  
32  
33 monitoring by TLC to reaction finish. The mixture was slowly poured into ice-water  
34  
35 with stirring and let stand overnight. The precipitated solid was collected and washed  
36  
37 with cold water to neutral pH. After drying, 215 mg of 2,4-dichloro-5-nitrobenzoic acid  
38  
39 was obtained in 91% yield, white powder, mp 148-150 °C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ ppm  
40  
41 8.15 (1H, s, ArH-3), 8.50 (1H, s, ArH-5).

42  
43 **Methyl 2,4-Dichloro-5-nitrobenzoate (6).** A solution of  
44  
45 2,4-dichloro-5-nitrobenzoic acid (235 mg, 1 mmol) in MeOH (10 mL) in the presence of  
46  
47 H<sub>2</sub>SO<sub>4</sub> (conc., 2 mL) was refluxed for 2 h. The mixture was poured into ice-water and let  
48  
49 stand overnight. The precipitated white solid was collected, and washed with cold water  
50  
51 to neutral. After drying, 215 mg of **6** was obtained in 86% yield, white powder, mp  
52  
53  
54  
55  
56  
57  
58  
59  
60

46-48 °C; <sup>1</sup>H NMR δ ppm 3.98 (3H, s, CH<sub>3</sub>), 7.71 (1H, s, ArH-3), 8.49 (1H, s, ArH-5).

### General Preparation of 4-Substituted

**5-Chloro-*N*'-(4-cyanophenyl)-2-nitroanilines (7-9).** To a solution of 5-substituted 2,4-dichloro-nitrobenzene (1 equiv) and *para*-cyanoaniline (1.1 equiv) in DMF (3 mL) was slowly added potassium *tert*-butoxide (2 equiv) at 0 °C (ice-water bath) with stirring and then for an additional 1 h at room temperature. The reaction was monitored by TLC until completion. The mixture was poured into ice-water and pH adjusted to 6 with aq HCl (5%). The solid crude product was collected, washed with cold water, and purified by CombiFlash medium-pressure column chromatography system.

### 5-Chloro-*N*'-(4-cyanophenyl)-4-trifluoromethyl-2-nitroanilines (7).

Starting with 260 mg (1 mmol) of commercially available 2,4-dichloro-5-nitrobenzotrifluoride (**4**) and 130 mg (1.1 mmol) of *para*-cyanoaniline to afford 281 mg of **7**, yield 82% yield, yellow solid, mp 180-182 °C; <sup>1</sup>H NMR δ ppm 7.40 (1H, s, ArH-6), 7.41 (2H, d, *J* = 8.4 Hz, ArH-2',6'), 7.78 (2H, d, *J* = 8.4 Hz, ArH-3',5'), 8.61 (1H, s, ArH-3), 9.78 (1H, s, NH); MS *m/z* (%) 359.2 (M+NH<sub>4</sub>, 100).

### 5-Chloro-*N*'-(4-cyanophenyl)-4-sulfonamide-2-nitroanilines (8).

Yield 33%, starting with 271 mg (1 mmol) of **5** and 130 mg (1.1 mmol) of *para*-cyanoaniline to afford 116 mg of **8**, yellow solid, mp 236-238 °C; <sup>1</sup>H NMR δ ppm 5.09 (2H, s, NH<sub>2</sub>), 7.39 (1H, s, ArH-6), 7.41 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 7.79 (2H, d, *J* = 8.8 Hz, ArH-3',5'), 8.99 (1H, s, ArH-3), 9.84 (1H, s, NH); MS *m/z* (%) 375.1 (M+Na, 100).

### 5-Chloro-*N*'-(4-cyanophenyl)-4-methoxycarbonyl-2-nitroanilines (9).

Yield 57%, starting with 250 mg (1 mmol) of **6** and 130 mg (1.1 mmol) of *para*-cyanoaniline to afford 189 mg of **9**, yellow solid, mp 198-202 °C; <sup>1</sup>H NMR δ ppm 3.95 (3H, s, CH<sub>3</sub>), 7.38 (2H, d, *J* = 8.4 Hz, ArH-2',6'), 7.42 (1H, s, ArH-6), 7.77 (2H, d, *J* = 8.4 Hz, ArH-3',5'), 8.92 (1H, s, ArH-3), 9.76 (1H, s, NH); MS *m/z* (%) 354.3 (M+Na,

1  
2  
3 100).  
4

5 **General Coupling Reaction of Diphenylether (under microwave**  
6 **irradiation) for 10a, 10c, 11c, and 11d.** A mixture of 4-substituted  
7  
8 *N*<sup>1</sup>-(4-cyanophenyl)-5-chloro-2-nitroaniline (1 equiv, **7** or **9**) and *para*-substituted  
9  
10 2,6-dimethylphenol (1.2 equiv) in DMF (3 mL) in the presence of anhydrous potassium  
11  
12 carbonate (2 equiv) was irradiated under microwave conditions with stirring at 190 °C  
13  
14 for 15 min. The mixture was poured into ice-water, adjusted to neutral pH with aq HCl  
15  
16 (5%), and extracted with EtOAc three times. After removal of organic solvent under  
17  
18 reduced pressure, crude product was purified by PTLC or flash column chromatography  
19  
20 (gradual eluant: petroleum ether/CH<sub>2</sub>Cl<sub>2</sub>).  
21  
22  
23

24  
25 ***N*<sup>1</sup>-(4'-Cyanophenyl)-5-(2'',6''-dimethyl-4''-formylphenoxy)-4-trifluoro**  
26 **methyl-2-nitroaniline (10a).** Starting with 171 mg (0.5 mmol) of **7** and 90 mg (0.6  
27  
28 mmol) of 2,6-dimethyl-*para*-formylphenol to afford 182 mg of **10a**, yield 80%, yellow  
29  
30 solid, mp 192-194 °C; <sup>1</sup>H NMR δ ppm 2.21 (6H, s, 2 × CH<sub>3</sub>), 6.24 (1H, s, ArH-6), 7.08  
31  
32 (2H, d, *J* = 8.4 Hz, ArH-2',6'), 7.51 (2H, d, *J* = 8.4 Hz, ArH-3',5'), 7.67 (2H, s,  
33  
34 ArH-3'',5''), 8.68 (1H, s, ArH-3), 9.92 (1H, s, NH), 9.97 (1H, s, CHO); MS *m/z* (%)  
35  
36 456.4 (M+1, 100).  
37  
38  
39

40  
41 ***N*<sup>1</sup>-(4'-Cyanophenyl)-5-(2'',6''-dimethyl-4''-formylphenoxy)-4-methoxy**  
42 **carbonyl-2-nitroaniline (10c).** Starting with 166 mg (0.5 mmol) of **9** and 90 mg (0.6  
43  
44 mmol) of 2,6-dimethyl-*para*-formylphenol to afford 150 mg of **10c**, yield 67%, yellow  
45  
46 solid, mp 220-222 °C; <sup>1</sup>H NMR δ ppm 2.22 (6H, s, 2 × CH<sub>3</sub>), 3.97 (3H, s, OCH<sub>3</sub>), 6.23  
47  
48 (1H, s, ArH-6), 7.06 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 7.48 (2H, d, *J* = 8.8 Hz, ArH-3',5'),  
49  
50 7.65 (2H, s, ArH-3'',5''), 9.02 (1H, s, ArH-3), 9.88 (1H, s, NH), 9.96 (1H, s, CHO); MS  
51  
52 *m/z* (%) 446.1 (M+1, 100).  
53  
54  
55

56 ***N*<sup>1</sup>-(4'-Cyanophenyl)-5-(4''-cyano-2'',6''-dimethylphenoxy)-4-trifluoro**  
57  
58  
59  
60

1  
2  
3 **methyl-2-nitroaniline (11c)**. Starting with 171 mg (0.5 mmol) of **7** and 88 mg (0.6  
4 mmol) of *para*-cyano-2,6-dimethylphenol to afford 150 mg of **11c**, yield 66%, yellow  
5 solid, mp 182-184 °C; <sup>1</sup>H NMR δ ppm 2.17 (6H, s, 2 × CH<sub>3</sub>), 6.21 (1H, s, ArH-6), 7.09  
6 (2H, d, *J* = 8.4 Hz, ArH-2',6'), 7.44 (2H, s, ArH-3'',5''), 7.56 (2H, d, *J* = 8.4 Hz,  
7 ArH-3',5'), 8.67 (1H, s, ArH-3), 9.92 (1H, s, NH); MS *m/z* (%) 453.2 (M+1, 100).  
8  
9

10  
11  
12  
13  
14 ***N*<sup>1</sup>-(4'-Cyanophenyl)-5-(2'',6''-dimethyl-4''-nitrophenoxy)-4-trifluorom**

15  
16 **ethyl-2-nitroaniline (11d)**. Starting with 171 mg (0.5 mmol) of **7** and 100 mg (0.6  
17 mmol) of 2,6-dimethyl-*para*-nitrophenol to afford 215 mg of **11d**, yield 91%, yellow  
18 solid, mp 240-242 °C; <sup>1</sup>H NMR δ ppm 2.24 (6H, s, 2 × CH<sub>3</sub>), 6.22 (1H, s, ArH-6), 7.10  
19 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 7.55 (2H, d, *J* = 8.8 Hz, ArH-3',5'), 8.02 (2H, s,  
20 ArH-3'',5''), 8.69 (1H, s, ArH-3), 9.92 (1H, s, NH); MS *m/z* (%) 473.3 (M+1, 100).  
21  
22

23  
24  
25  
26  
27 ***N*<sup>1</sup>-(4'-Cyanophenyl)-5-(2'',6''-dimethyl-4''-formylphenoxy)-4-sulfamo**

28  
29  
30 **yl-2-nitroaniline (10b)**. A mixture of 353 mg (1 mmol) of **8** and 180 mg (1.2 mmol) of  
31 2,6-dimethyl-*para*-formylphenol in DMF in the presence of anhydrous potassium  
32 carbonate (2 equiv) was heated at 130 °C for 5 h. The mixture was poured into ice-water,  
33 adjusted to neutral pH with aq HCl (5%), and extracted with EtOAc three times. After  
34 removal of organic solvent under reduced pressure, crude product was purified by PTLC  
35 or medium-pressure column (gradual eluant: petroleum ether/CH<sub>2</sub>Cl<sub>2</sub>) to afford 310 mg  
36 of **10b**, yield 67%, yellow solid, mp 178-180 °C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ ppm 2.26 (6H,  
37 s, 2 × CH<sub>3</sub>), 6.35 (1H, s, ArH-6), 7.49 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 7.56 (2H, s,  
38 ArH-3'',5''), 7.82 (2H, d, *J* = 8.8 Hz, ArH-3',5'), 8.24 (1H, s, ArH-3), 9.76 (1H, s, NH),  
39 9.88 (1H, s, -CHO); MS *m/z* (%) 465.2 (M-1, 100).  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52 ***N*<sup>1</sup>-(4'-Cyanophenyl)-5-(2'',6''-dimethyl-4''-(3-oxobut-1-enyl)phenoxy)-**

53  
54 **4-trifluoromethyl-2-nitroaniline (11a)**. To a solution of **10a** (228 mg, 0.5 mmol) in  
55 acetone (10 mL) and MeOH (3 mL) was added 10% aq NaOH (2 mL) slowly at 0 °C  
56  
57  
58  
59  
60

(ice-water bath) with stirring for about 10 min and then for additional 1 h at room temperature. After the reaction was completed, the mixture was poured into ice-water, and the pH adjusted with 5% aq. HCl to neutral. The solid crude product was collected, washed with water, and purified on a flash silica gel column (eluent: CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 100/1) to afford 138 mg of **11a**, 56% yield, yellow solid, mp 190-192 °C. <sup>1</sup>H NMR δ ppm 2.14 (6H, s, 2 × CH<sub>3</sub>), 2.42 (3H, s, COCH<sub>3</sub>), 6.27 (1H, s, ArH-6), 6.68 (1H, s, *J* = 16.4 Hz, =CH), 7.09 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 7.30 (2H, s, ArH-3'',5''), 7.43 (1H, s, *J* = 16.4 Hz, CH=), 7.51 (2H, d, *J* = 8.8 Hz, ArH-3',5'), 8.66 (1H, s, ArH-3), 9.89 (1H, s, NH); MS *m/z* (%) 496.5 (M+1, 100).

***N*'-(4'-Cyanophenyl)-5-(2'',6''-dimethyl-4''-hydroxymethylphenoxy)-4-hydroxymethyl-2-nitroaniline (11e)**. To a solution of LiBH<sub>4</sub> (5 mmol) in THF (5 mL) was added dropwise 223 mg (0.5 mmol) of **10c** in THF (5 mL) at r.t. The mixture was stirred for 15 min and then 1-2 mL MeOH was added, and stirring continued for 1 h. The mixture was poured into ice-water, pH was adjusted to 2-3 with 5% aq HCl, and the resulting solution extracted with EtOAc three times. After removal of organic solvent in vacuo, crude product was purified by PTLC or medium-pressure column (eluent: PE/EtOAc = 3/1) to afford 178 mg of **11e**, 85% yield, yellow solid, mp 216-218 °C; <sup>1</sup>H NMR δ ppm 2.13 (6H, s, 2 × CH<sub>3</sub>), 4.66 and 4.88 (each 2H, d, CH<sub>2</sub>O), 6.28 (1H, s, ArH-6), 7.03 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 7.12 (2H, s, ArH-3'',5''), 7.47 (2H, d, *J* = 8.8 Hz, ArH-3',5'), 8.38 (1H, s, ArH-3), 9.70 (1H, s, NH); MS *m/z* (%) 442.4 (M+Na, 100).

**General Preparation of 4-Substituted *N*'-(4'-Cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethylphenoxy)-2-nitroaniline (12a-12c)**. To a solution of diethylcyanomethyl phosphonate [(EtO)<sub>2</sub>P(O)CH<sub>2</sub>CN, 266 mg, 1.5 mmol] in THF (15 mL) was added *t*-BuOK (168 mg, 1.5 mmol) at 0 °C

1  
2  
3 (ice-water bath) with stirring for 30 min. The solution of an aldehyde (**10a**, **10b**, or **10c**,  
4 1 mmol) in THF (15 mL) was added dropwise into the above mixture at rt and stirring  
5 continued for about 3 h until the reaction was completed. The mixture was poured into  
6 water and extracted with EtOAc three times. After removal of solvent under reduced  
7 pressure, the crude product was purified by a silica gel column using the  
8 medium-pressure system of CombiFlash companion (gradual eluant: MeOH / CH<sub>2</sub>Cl<sub>2</sub>,  
9 0-4.5%).

10  
11  
12 ***N*<sup>1</sup>-(4'-Cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethylphenoxy)-4-trifl**  
13 **uoromethyl-2-nitroaniline (12a)**. Starting with 455 mg (1 mmol) of **10a** and 266 mg  
14 (1.5 mmol) of (EtO)<sub>2</sub>P(O)CH<sub>2</sub>CN to afford 416 mg of pure **12a**, 87% yield, yellow solid,  
15 mp 248-250 °C; <sup>1</sup>H NMR δ ppm 2.15 (6H, s, 2 × CH<sub>3</sub>), 5.85 (1H, d, *J* = 16.4 Hz, =CH),  
16 6.27 (1H, s, ArH-6), 7.10 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 7.21 (2H, s, ArH-3'',5''), 7.32  
17 (1H, d, *J* = 16.4 Hz, CH=), 7.52 (2H, d, *J* = 8.8 Hz, ArH-3',5'), 8.67 (1H, s, ArH-3),  
18 9.91 (1H, s, NH); MS *m/z* (%) 501.1 (M+Na, 100).

19  
20  
21 ***N*<sup>1</sup>-(4'-Cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethylphenoxy)-4-sulf**  
22 **amoyl-2-nitroaniline (12b)**. Starting with **10b** (466 mg, 1 mmol) and 266 mg (1.5  
23 mmol) of (EtO)<sub>2</sub>P(O)CH<sub>2</sub>CN to afford 218 mg of **12b**, yield 45%, yellow solid, mp  
24 198-200 °C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ ppm 2.16 (6H, s, 2 × CH<sub>3</sub>), 6.38 (1H, d, *J* = 16.4 Hz,  
25 =CH), 6.54 (1H, s, ArH-6), 7.32 (2H, s, ArH-3'',5''), 7.51 (2H, d, *J* = 8.8 Hz, ArH-2',6'),  
26 7.52 (1H, d, *J* = 16.4 Hz, =CHCN), 7.85 (2H, d, *J* = 8.8 Hz, ArH-3',5'), 8.25 (1H, s,  
27 ArH-3), 9.79 (1H, s, NH); MS *m/z* (%) 488 (M-1, 100).

28  
29  
30 ***N*<sup>1</sup>-(4'-Cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethylphenoxy)-4-met**  
31 **hoxycarbonyl-2-nitroaniline (12c)**. Starting with 445 mg (1 mmol) of **10c** and 266  
32 mg (1.5 mmol) of (EtO)<sub>2</sub>P(O)CH<sub>2</sub>CN to afford 412 mg of **12c**, 88% yield, yellow solid,  
33 mp 260-262 °C; <sup>1</sup>H NMR δ ppm 2.16 (6H, s, 2 × CH<sub>3</sub>), 3.96 (3H, s, OCH<sub>3</sub>), 5.84 (1H, d,  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  $J = 16.4$  Hz, =CH), 6.26 (1H, s, ArH-6), 7.08 (2H, d,  $J = 8.8$  Hz, ArH-2',6'), 7.20 (2H, s,  
4 ArH-3'',5''), 7.32 (1H, d,  $J = 16.4$  Hz, CH=), 7.50 (2H, d,  $J = 8.8$  Hz, ArH-3',5'), 9.00  
5  
6  
7 (1H, s, ArH-3), 9.87 (1H, s, NH); MS  $m/z$  (%) 469.4 (M+1, 100).

8  
9  
10 ***N*'-(4'-Cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethylphenoxy)-4-carb**  
11 **oxy-2-nitroaniline (12d).** To a solution of **12c** (234 mg, 0.5 mmol) in THF (15 mL)  
12 and MeOH (10 mL) was slowly added NaOH aqueous solution (80 mg NaOH in 4 mL  
13 of water) at rt with stirring for 4 h. The mixture was poured into ice-water, pH adjusted  
14 to 2–3 with 5% aq HCl, and solid was collected and washed with cold water to neutral.  
15 The crude product was purified on a silica gel column using a CombiFlash system  
16 (gradual eluant: MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 0-4.5%) to afford 204 mg of pure **12d** in 90% yield,  
17 yellow solid, mp 262-265 °C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ ppm 2.06 (6H, s, 2 × CH<sub>3</sub>), 5.95  
18 (1H, s, ArH-6), 6.44 (1H, d,  $J = 16.4$  Hz, =CH), 7.22 ( 2H, d,  $J = 8.8$  Hz, ArH-2',6'),  
19 7.47 (2H, s, ArH-3'',5''), 7.58 (1H, d,  $J = 16.4$  Hz, CH=), 7.65 (2H, d,  $J = 8.8$  Hz,  
20 ArH-3',5'), 8.72 (1H, s, ArH-3), 9.79(1H, s, NH), 13.21 (1H, s, COOH); MS  $m/z$  (%)  
21 453.4 (M-1, 100).  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 **Preparation of Amidated Compounds (12e-g).** To a solution of **12d** (0.5  
37 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added dropwise SOCl<sub>2</sub> (0.5 mL) at rt and then heated at  
38 reflux for 3 h. After removal of solvent, the obtained brown solid was dissolved in dry  
39 THF (5 mL), followed by addition of an amine aqueous solution (1 mL, excess, NH<sub>3</sub>,  
40 methylamine, or hydrazine) with stirring for an additional 30 min at 0 °C (ice-bath) until  
41 the reaction was completed. The mixture was poured into ice-water and pH was adjusted  
42 to neutral with 5% aq. HCl. The solid was collected, washed with cold water, and dried.  
43 The crude product was purified on a flash silica gel column (gradual eluant:  
44 MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 0-4.5%) using a CombiFlash syetem.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

56 ***N*'-(4'-Cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethylphenoxy)-4-**  
57  
58  
59  
60

1  
2  
3 **carbamoyl-2-nitroaniline (12e)**. Starting with 227 mg of **12d** (0.5 mmol) in CH<sub>2</sub>Cl<sub>2</sub>  
4 (5 mL), SOCl<sub>2</sub> (0.5 mL) was added dropwise to obtain acyl chloride (brown solid),  
5 which was dissolved in dry THF (5 mL) and added to aqueous ammonia solution (1 mL)  
6 with stirring for 30 min at 0 °C (ice-bath) until the reaction was completed. After general  
7 work-up as described above, 198 mg of **12e** was obtained in 87% yield, yellow solid, mp  
8 278-280 °C; <sup>1</sup>H NMR δ ppm 2.16 (6H, s, 2 × CH<sub>3</sub>), 5.88 (1H, d, *J* = 16.4 Hz, =CH), 6.29  
9 (1H, s, ArH-6), 7.08 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 7.24 (2H, s, ArH-3'',5''), 7.33 (1H, d,  
10 *J* = 16.4 Hz, CH=), 7.50 (2H, d, *J* = 8.8 Hz, ArH-3',5'), 9.30 (1H, s, ArH-3), 9.82 (1H, s,  
11 NH); MS *m/z* (%) 454.3 (M+1, 100).

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23 ***N*'-(4'-Cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethylphenoxy)-4-met**  
24  
25 **hylcarbamoyl-2-nitroaniline (12f)**. Starting with **12d** (227 mg, 0.5 mmol) with  
26 SOCl<sub>2</sub> (0.5 mL), followed by dry THF (5 mL) and aqueous methylamine solution  
27 (25-30%, 1 mL) at ice-bath with stirring for 30 min. After the same work-up as above,  
28 140 mg of pure **12f** was obtained in 60% yield, yellow solid, mp 218-220 °C; <sup>1</sup>H NMR δ  
29 ppm 2.17 (6H, s, 2 × CH<sub>3</sub>), 3.08 (3H, d, CH<sub>3</sub>), 5.88 (1H, d, *J* = 16.4Hz, =CH), 6.28 (1H,  
30 s, ArH-6), 7.07 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 7.25 (2H, s, ArH-3'',5''), 7.34 (1H, d, *J* =  
31 16.4Hz, CH=), 7.49 (2H, d, *J* = 8.8 Hz, ArH-3',5'), 7.50 (1H, NMe), 9.29 (1H, s, ArH-3),  
32 9.78 (1H, s, NH); MS *m/z* (%) 468.3 (M+1, 100).

33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43 ***N*'-(4'-Cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethylphenoxy)-4-hyd**  
44 **razide-2-nitroaniline (12g)**. Starting with **12d** (140 mg, 0.30 mmol) with SOCl<sub>2</sub> (0.50  
45 mL), followed by dry THF (3 mL) and dropped slowly into hydrazine hydrate aqueous  
46 solution (85%, 1 mL) at rt with stirring for 1 h. After the same work-up as above, crude  
47 product was purified on a flash silica gel column (gradual eluant: MeOH/CH<sub>2</sub>Cl<sub>2</sub>,  
48 0-4.5%) to afford 116 mg of pure **12g** in 80% yield, yellow solid; <sup>1</sup>H NMR δ ppm 2.13  
49 (6H, s, 2×CH<sub>3</sub>) 5.82 (1H, d, *J* = 16.4 Hz, =CHCN), 6.30 (1H, s, ArH-6), 6.98 (2H, d, *J* =  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 8.8 Hz, ArH-2',6'), 7.21 (2H, s, ArH-3'', 5''), 7.33 (1H, d,  $J = 16.4$  Hz, =CHAr), 7.53  
4  
5 (2H, d,  $J = 8.8$  Hz, ArH-3',5'), 9.20 (H, s, ArH-3), 9.81 (1H, s, NH); MS  $m/z$  (%) 469  
6  
7 (M + 1, 100).

9  
10 ***N*'-(4'-Cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethylphenoxy)-4-hyd**  
11 **roxymethyl-2-nitroaniline (12h).** The preparation was the same as that of **11e**.  
12 Starting with 234 mg (0.5 mmol) of **12c**, reduction with LiBH<sub>4</sub> afforded 100 mg of pure  
13 **12h** in 91% yield, yellow solid, mp 232-234 °C; <sup>1</sup>H NMR δ ppm 2.15 (6H, s, 2 × CH<sub>3</sub>),  
14 4.89 (2H, s, OCH<sub>2</sub>), 5.85 (1H, d,  $J = 16.4$  Hz, =CH), 6.27 (1H, s, ArH-6), 7.05 (2H, d,  $J$   
15 = 8.8 Hz, ArH-2',6'), 7.21 (2H, s, ArH-3'',5''), 7.28 (1H, d,  $J = 16.4$  Hz, CH=), 7.47 (2H,  
16 d,  $J = 8.8$  Hz, ArH-3',5'), 8.41 (1H, s, ArH-3), 9.70 (1H, s, NH); MS  $m/z$  (%) 439.3  
17  
18 (M-1, 100).  
19  
20  
21  
22  
23  
24  
25  
26

27 **General Preparation of 4-Substituted 1,5-Diarylbenzene-1,2-diamines**  
28 **(13a, 14a-f, and 14h).** To a solution of a diaryl-nitrobenzene (1 equiv) in THF and  
29 water (30 mL, v/v 1:1) was added aqueous ammonia solution (25%) and sodium  
30 hydrosulfite (10 equiv) successively. The mixture was stirred at rt for 2 h monitored by  
31 TLC (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 60:1) until reaction was completed. The mixture was poured into  
32 ice-water and extracted with EtOAc several times. After removal of organic solvent  
33 under reduced pressure, crude product was purified on a flash column chromatograph  
34 (gradual eluant: MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 0-4.5%) with a CombiFlash separation system to obtain  
35 pure target compound.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 **(*E*)-*N*'-(4'-Cyanophenyl)-5-(2'',6''-dimethyl-4''-(3-oxobut-1-enyl)pheno**  
48 **xy)-4-trifluoromethylbenzene-1,2-diamine (13a).** Starting with 495 mg (1 mmol)  
49 of **11a** to afford 316 mg of **13a**, yield 68%, brown solid, mp > 300 °C; <sup>1</sup>H NMR δ ppm  
50 2.14 (6H, s, 2 × CH<sub>3</sub>), 2.37 (3H, s, COCH<sub>3</sub>), 5.71 (1H, s, NH), 6.21 (1H, s, ArH-6), 6.64  
51  
52 (2H, d,  $J = 8.8$  Hz, ArH-2',6'), 6.65 (1H, s,  $J = 16.4$  Hz, =CH), 7.16 (1H, s, ArH-3), 7.27  
53  
54  
55  
56  
57  
58  
59  
60

(2H, s, ArH-3'',5''), 7.42 (2H, d,  $J = 8.8$  Hz, ArH-3',5'), 7.43 (1H, s,  $J = 16.4$ Hz, CH=);  
MS  $m/z$  (%) 466.2 (M+1, 100); HPLC purity 97.9%.

**(*E*)-*N*<sup>1</sup>-(4'-Cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethylphenoxy)-4-t  
rifluoromethylbenzene-1,2-diamine (14a).** Starting with 478 mg (1 mmol) of **12a**  
to afford 112 mg of **14a**, yield 25%, white solid, mp 224-226 °C; <sup>1</sup>H NMR  $\delta$  ppm 2.15  
(6H, s, 2  $\times$  CH<sub>3</sub>), 5.68 (1H, s, NH), 5.80 (1H, d,  $J = 16.8$  Hz, =CH), 6.18 (1H, s, ArH-6),  
6.63 (2H, d,  $J = 8.8$  Hz, ArH-2',6'), 7.16 (1H, s, ArH-3), 7.18 (2H, s, ArH-3'',5''), 7.27  
(1H, d,  $J = 16.8$  Hz, CH=), 7.43 (2H, d,  $J = 8.8$  Hz, ArH-3',5'); MS  $m/z$  (%) 449 (M+1,  
100); HPLC purity 97.3%.

**(*E*)-*N*<sup>1</sup>-(4'-Cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethylphenoxy)-4-  
sulfamoylbenzene-1,2-diamine (14b).** Starting with 489 mg (1 mmol) of **12b** to  
afford 184 mg of **14b** in 40% yield, brown solid, mp 135-137 °C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  
 $\delta$  ppm 2.14 (6H, s, 2  $\times$  CH<sub>3</sub>), 4.59 (2H, s, NH<sub>2</sub>), 6.37 (1H, d,  $J = 16.8$  Hz, =CH), 6.78  
(1H, s, ArH-6), 6.93 (1H, d,  $J = 16.8$  Hz, CH=), 6.95 (2H, d,  $J = 8.8$  Hz, ArH-2',6'),  
7.30 (2H, s, ArH-3'',5''), 7.61 (2H, d,  $J = 8.8$  Hz, ArH-3',5'), 8.20 (1H, s, ArH-3); MS  
 $m/z$  (%) 460.3 (M+1,100); HPLC purity 95.8%.

**(*E*)-*N*<sup>1</sup>-(4'-Cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethylphenoxy)-4-  
methoxycarbonylbenzene-1,2-diamine (14c).** Starting with 468 mg (1 mmol) of  
**12c** to afford 280 mg of **14c**, yield 64%, brown solid, mp 240-242 °C. <sup>1</sup>H NMR  $\delta$  ppm  
2.16 (6H, s, 2  $\times$  CH<sub>3</sub>), 3.93 (3H, s, OCH<sub>3</sub>), 5.78 (1H, s, NH), 5.80 (1H, d,  $J = 16.8$  Hz,  
=CH), 6.20 (1H, s, ArH-6), 6.67 (2H, d,  $J = 8.8$  Hz, ArH-2',6'), 7.17 (2H, s, ArH-3'',5''),  
7.31 (1H, d,  $J = 16.8$  Hz, CH=), 7.42 (2H, d,  $J = 8.8$  Hz, ArH-3',5'), 7.45 (1H, s, ArH-3);  
MS  $m/z$  (%) 439.3 (M+1, 100); HPLC purity 96.6%.

**(*E*)-4-Carboxy-*N*<sup>1</sup>-(4'-cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethyl  
phenoxy)benzene-1,2-diamine (14d).** Starting with 454 mg (1 mmol) of **12d** to

1  
2  
3 afford 148 mg of **14d**, yield 35%, brown solid, mp 226-228 °C; <sup>1</sup>H NMR δ ppm 2.19  
4 (6H, s, 2 × CH<sub>3</sub>), 5.84 (1H, d, *J* = 16.8 Hz, =CH), 6.04 (1H, s, NH), 6.27 (1H, s, ArH-6),  
5  
6 6.75 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 7.22 (2H, s, ArH-3'',5''), 7.32 (1H, d, *J* = 16.8 Hz,  
7  
8 CH=), 7.44 (2H, d, *J* = 8.8 Hz, ArH-3',5'), 7.72 (1H, s, ArH-3); MS *m/z* (%) 423.2 (M-1,  
9  
10 100); HPLC purity 95.6%.

11  
12  
13  
14 **(*E*)-4-Carbamoyl-*N*<sup>1</sup>-(4'-cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethy**  
15  
16 **lphenoxy)benzene-1,2-diamine (14e)**. Starting with 453 mg (1 mmol) of **12e** to  
17  
18 afford 266 mg of **14e**, yield 63%, white solid, mp 290-292 °C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ  
19  
20 ppm 2.10 (6H, s, 2 × CH<sub>3</sub>), 4.76 (2H, s, NH<sub>2</sub>), 6.00 (1H, s, ArH-6), 6.39 (1H, d, *J* = 16.4  
21  
22 Hz, =CH), 6.63 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 7.47 (2H, s, ArH-3'',5''), 7.47 (2H, d, *J* =  
23  
24 8.8 Hz, ArH-3',5'), 7.56 (1H, d, *J* = 16.4 Hz, CH=), 7.60 (1H, s, ArH-3), 8.20 (1H, s,  
25  
26 NH); MS *m/z* (%) 424.2 (M+1, 100); HPLC purity 98.2%.

27  
28  
29  
30 **(*E*)-*N*<sup>1</sup>-(4'-Cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethylphenoxy)-4-**  
31  
32 **methylcarbamoylbenzene-1,2-diamine (14f)**. Starting with 467 mg (1 mmol) of  
33  
34 **12f** to afford 135 mg of **14f**, yield 31%, brown solid, mp 112-114 °C; <sup>1</sup>H NMR δ ppm  
35  
36 2.16 (6H, s, 2 × CH<sub>3</sub>), 3.07 (3H, d, NCH<sub>3</sub>), 5.80 (1H, s, NH), 5.83 (1H, d, *J* = 16.8 Hz,  
37  
38 =CH), 6.18 (1H, s, ArH-6), 6.65 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 7.21 (2H, s, ArH-3'',5''),  
39  
40 7.32 (1H, d, *J* = 16.8 Hz, CH=), 7.41 (2H, d, *J* = 8.8 Hz, ArH-3',5'), 7.81 (1H, s, ArH-3);  
41  
42 MS *m/z* (%) 438.4 (M+1, 100); HPLC purity 100.0%.

43  
44  
45 **(*E*)-*N*<sup>1</sup>-(4'-Cyanophenyl)-5-(4''-cyanovinyl-2'',6''-dimethylphenoxy)-4-**  
46  
47 **hydroxymethylbenzene-1,2-diamine (14h)**. Starting with 440 mg (1 mmol) of **12h**  
48  
49 to afford 332 mg of **14h**, yield 81%, brown solid, mp 186-188 °C. <sup>1</sup>H NMR δ ppm 2.13  
50  
51 (6H, s, 2 × CH<sub>3</sub>), 4.87 (2H, s, ArCH<sub>2</sub>O), 5.50 (1H, s, NH), 5.79 (1H, d, *J* = 16.8 Hz,  
52  
53 =CH), 6.03 (1H, s, ArH-6), 6.55 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 6.94 (1H, s, ArH-3),  
54  
55 7.17 (2H, s, ArH-3'',5''), 7.30 (1H, d, *J* = 16.8 Hz, CH=), 7.40 (2H, d, *J* = 8.8 Hz,  
56  
57  
58  
59  
60

ArH-3',5'); MS  $m/z$  (%) 411.3 (M+1, 100); HPLC purity 99.9%.

### General Procedure for Catalytic Hydrogenation to Prepare

**4-Substituted 1,5-Diarylbenzene-1,2-diamines (13b-e and 15a-i).** A solution of a diaryl-nitrobenzene (1 equiv) in 30 mL of anhydrous EtOH in the presence of excess Pd/C (5%) was shaken with hydrogen gas under 30-40 p.s.i. until the hydrogen was no longer absorbed (ca. 2 h). The catalyst was filtered from the solution and washed with EtOH several times (ca. 20 mL). After the solvent was removed under reduced pressure, the residue was purified by flash column chromatography (gradual eluant: MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 0-4.5%) to obtain pure desired product.

***N*<sup>1</sup>-(4'-Cyanophenyl)-5-(2'',6''-dimethyl-4''-(3-oxobutyl)phenoxy)-4-trifluoromethylbenzene-1,2-diamine (13b).** Starting with 495 mg (1 mmol) of **11a** to afford 234 mg of **13b**, yield 50%, brown solid, mp 94-96 °C, <sup>1</sup>H NMR δ ppm 2.07 (6H, s, 2 × CH<sub>3</sub>), 2.14 (3H, s, COCH<sub>3</sub>), 2.73 (2H, t, *J* = 7.2 Hz, CH<sub>2</sub>CO), 2.80 (2H, t, *J* = 7.2 Hz, ArCH<sub>2</sub>), 6.21 (1H, s, ArH-6), 6.64 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 6.88 (2H, s, ArH-3'',5''), 7.14 (1H, s, ArH-3), 7.43 (2H, d, *J* = 8.8 Hz, ArH-3',5'); MS  $m/z$  (%) 468.4 (M+1, 100); HPLC purity 97.4 %.

**5-(4''-Cyano-2'',6''-dimethylphenoxy)-*N*<sup>1</sup>-(4'-cyanophenyl)-4-trifluoromethylbenzene-1,2-diamine (13c).** Starting with 452 mg (1 mmol) of **11c** and to afford 329 mg of **13c**, yield 78%, white solid, mp 240-242 °C; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ ppm 2.09 (6H, s, 2 × CH<sub>3</sub>), 4.93 (2H, s, NH<sub>2</sub>), 5.76 (1H, s, NH) 6.06 (1H, s, ArH-6), 6.65 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 7.18 (1H, s, ArH-3), 7.50 (2H, d, *J* = 8.8 Hz, ArH-3',5'), 7.69 (2H, s, ArH-3'',5''); MS  $m/z$  (%) 423 (M+1, 100); HPLC purity 99.9 %.

**5-(4''-Amino-2'',6''-dimethylphenoxy)-*N*<sup>1</sup>-(4'-cyanophenyl)-4-trifluoromethylbenzene-1,2-diamine (13d).** Starting with 472 mg (1 mmol) of **11d** to afford 316 mg of **13c**, yield 77%, brown solid, mp 194-196 °C; <sup>1</sup>H NMR δ ppm 2.02 (6H, s, 2

1  
2  
3 × CH<sub>3</sub>), 5.71 (1H, s, NH), 6.30 (1H, s, ArH-6), 6.39 (2H, s, ArH-3'',5''), 6.65 (2H, d, *J* =  
4  
5 8.8 Hz, ArH-2',6'), 7.12 (1H, s, ArH-3), 7.43 (2H, d, *J* = 8.8 Hz, ArH-3',5'); MS *m/z* (%)  
6  
7 413.4 (M+1, 100); HPLC purity 96.2 %.

9  
10 ***N*'-(4'-Cyanophenyl)-5-(2'',6''-dimethyl-4''-hydroxymethylphenoxy)-4-**  
11 **hydroxymethylbenzene-1,2-diamine (13e).** Starting with 419 mg (1 mmol) of **11e**  
12 to afford 237 mg of **13e**, yield 61%, brown solid, mp 190-192 °C; <sup>1</sup>H NMR δ ppm 2.12  
13  
14 (6H, s, 2 × CH<sub>3</sub>), 3.52 (2H, s, NH<sub>2</sub>), 4.63 and 4.87 (each 2H, s, CH<sub>2</sub>O), 5.48 (1H, s, NH),  
15  
16 6.06 (1H, s, ArH-6), 6.54 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 6.92 (1H, s, ArH-3), 7.08 (2H,  
17  
18 s, ArH-3'',5''), 7.39 (2H, d, *J* = 8.8 Hz, ArH-3',5'); MS *m/z* (%) 390.3 (M+1, 100);  
19  
20 HPLC purity 99.4 %.

21  
22 **5-(4''-Cyanoethyl-2'',6''-dimethylphenoxy)-*N*'-(4'-cyanophenyl)-4-trifl**  
23 **uoromethylbenzene-1,2-diamine (15a).** Starting with 478 mg (1 mmol) of **12a** to  
24 afford 140 mg of **15a**, yield 31%, brown solid, mp 172-174 °C; <sup>1</sup>H NMR δ ppm 2.11 (6H,  
25  
26 s, 2 × CH<sub>3</sub>), 2.61 (2H, t, *J* = 7.2 Hz, CH<sub>2</sub>CN), 2.87 (2H, t, *J* = 7.2 Hz, ArCH<sub>2</sub>), 5.72 (1H,  
27  
28 s, NH), 6.20 (1H, s, ArH-6), 6.64 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 6.94 (2H, s, ArH-3'',5''),  
29  
30 7.14 (1H, s, ArH-3), 7.44 (2H, d, *J* = 8.8 Hz, ArH-3',5'); MS *m/z* (%) 451.1 (M+1, 100);  
31  
32 HPLC purity 99.7 %.

33  
34 **5-(4''-Cyanoethyl-2'',6''-dimethylphenoxy)-*N*'-(4'-cyanophenyl)-4-sulf**  
35 **amoylbenzene-1,2-diamine (15b).** Starting with 489 mg (1 mmol) of **12b** to afford  
36  
37 263 mg of **15b**, yield 57%, brown solid, mp 140-142 °C; <sup>1</sup>H NMR δ ppm 2.13 (6H, s, 2  
38  
39 × CH<sub>3</sub>), 2.64 (2H, t, *J* = 6.8 Hz, CH<sub>2</sub>), 2.86 (2H, t, *J* = 6.8 Hz, ArCH<sub>2</sub>), 6.14 (1H, s, NH),  
40  
41 6.33 (1H, s, ArH-6), 6.88 (1H, s, ArH-3), 6.93 (2H, s, ArH-3'',5''), 7.06 (2H, d, *J* = 8.8  
42  
43 Hz, ArH-2',6'), 7.57 (2H, d, *J* = 8.8 Hz, ArH-3',5'); MS *m/z* (%) 460.2 (M-1, 100);  
44  
45 HPLC purity 100.0%

46  
47 **5-(4''-Cyanoethyl-2'',6''-dimethylphenoxy)-*N*'-(4'-cyanophenyl)-4-met**  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **hoxycarbonylbenzene-1,2-diamine (15c)**. Starting with 468 mg (1 mmol) of **12c**  
4  
5 to afford 207 mg of **15c**, yield 47%, white solid, mp 236-238 °C; <sup>1</sup>H NMR δ ppm 2.12  
6  
7 (6H, s, 2 × CH<sub>3</sub>), 2.61 (2H, t, *J* = 7.2 Hz, CH<sub>2</sub>), 2.87 (2H, t, *J* = 7.2 Hz, ArCH<sub>2</sub>), 3.93  
8  
9 (3H, s, OCH<sub>3</sub>), 5.90 (1H, s, NH), 6.23 (1H, s, ArH-6), 6.69 (2H, d, *J* = 9.2 Hz,  
10  
11 ArH-2',6'), 6.93 (2H, s, ArH-3'',5''), 7.43 (2H, d, *J* = 9.2 Hz, ArH-3',5'), 7.45 (1H, s,  
12  
13 ArH-3); MS *m/z* (%) 441.5 (M+1, 15); HPLC purity 100.0%.

16 **4-Carboxy-5-(4''-cyanoethyl-2'',6''-dimethylphenoxy)-N<sup>1</sup>-(4'-cyanophe**  
17  
18 **nyl)benzene-1,2-diamine (15d)**. Starting with 454 mg (1 mmol) of **12d** to afford 141  
19  
20 mg of **15d**, yield 33%, white solid, mp 234-236 °C; <sup>1</sup>H NMR δ ppm 2.16 (6H, s, 2 ×  
21  
22 CH<sub>3</sub>), 2.64 (2H, t, *J* = 7.2 Hz, CH<sub>2</sub>CN), 2.91 (2H, t, *J* = 7.2 Hz, ArCH<sub>2</sub>), 6.08 (1H, s,  
23  
24 NH), 6.31 (1H, s, ArH-6), 6.76 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 7.01 (2H, s, ArH-3'',5''),  
25  
26 7.46 (2H, d, *J* = 8.8 Hz, ArH-3',5'), 7.73 (1H, s, ArH-3); MS *m/z* (%) 425.2 (M-1, 100);  
27  
28 HPLC purity 94.8%.

31 **4-Carbanoyl-N<sup>1</sup>-(4'-cyanophenyl)-5-(4''-cyanoethyl-2'',6''-dimethylphe**  
32  
33 **noxy)benzene-1,2-diamine (15e)**. Starting with 453 mg (1 mmol) of **12e** to afford  
34  
35 378 mg of **15e**, yield 84%, brown solid, mp 274-276 °C; <sup>1</sup>H NMR δ ppm 2.14 (6H, s, 2 ×  
36  
37 CH<sub>3</sub>), 2.63 (2H, t, *J* = 7.2 Hz, CH<sub>2</sub>CN), 2.89 (2H, t, *J* = 7.2 Hz, ArCH<sub>2</sub>), 5.90 (1H, s,  
38  
39 NH), 6.23 (1H, s, ArH-6), 6.70 (2H, d, *J* = 8.8 Hz, ArH-2',6'), 6.99 (2H, s, ArH-3'',5''),  
40  
41 7.43 (2H, d, *J* = 8.8 Hz, ArH-3',5'), 7.79 (1H, s, ArH-3), 5.93, 7.85 (CONH<sub>2</sub>); MS *m/z*  
42  
43 (%) 426.4 (M+1, 100); HPLC purity 100.0%.

47 **5-(4''-Cyanoethyl-2'',6''-dimethylphenoxy)-N<sup>1</sup>-(4'-cyanophenyl)-4-met**  
48  
49 **hylcarbanoylbenzene-1,2-diamine (15f)**. Starting with 467 mg (1 mmol) of **12f** to  
50  
51 afford 289 mg of **15f**, yield 65.9%, brown solid, mp 110-112 °C; <sup>1</sup>H NMR δ ppm 2.10  
52  
53 (6H, s, 2 × CH<sub>3</sub>), 2.63 (2H, t, *J* = 7.2 Hz, CH<sub>2</sub>CN), 2.89 (2H, t, *J* = 7.2 Hz, ArCH<sub>2</sub>), 3.06  
54  
55 (3H, d, *J* = 4.8 Hz, NCH<sub>3</sub>), 5.85 (1H, s, NH), 6.21 (1H, s, ArH-6), 6.67 (2H, d, *J* = 8.8  
56  
57  
58  
59  
60

1  
2  
3 Hz, ArH-2',6'), 6.98 (2H, s, ArH-3'',5''), 7.42 (2H, d,  $J = 8.8$  Hz, ArH-3',5'), 7.82 (1H, s,  
4 ArH-3), 7.97 (1H, d,  $J = 4.8$  Hz, CONH); MS  $m/z$  (%) 440.4 (M+1, 100); HPLC purity  
5 96.5 %.

6  
7  
8  
9  
10 **5-(4''-Cyanoethyl-2'',6''-dimethylphenoxy)-N<sup>1</sup>-(4'-cyanophenyl)-4-hyd**  
11 **razide-2-aminoaniline (15g)**. Starting with 100 mg (0.21 mmol) of **12g** to afford 70  
12 mg of pure **15g**, yield 75%, white solid; <sup>1</sup>H NMR  $\delta$  ppm 2.11 (6H, s, 2  $\times$  CH<sub>3</sub>), 2.61 (2H,  
13 t,  $J = 6.8$  Hz, CH<sub>2</sub>CN), 2.86 (2H, t,  $J = 6.8$  Hz, CH<sub>2</sub>Ar), 6.21 (1H, s, ArH-6), 6.30 (1H, s,  
14 NH), 6.48 (2H, d,  $J = 8.8$  Hz, ArH-2',6'), 6.98 (2H, s, ArH-3'', 5''), 7.00 (1H, s, ArH-3),  
15 7.43 (1H, d,  $J = 8.8$  Hz, ArH-3',5'); MS  $m/z$  (%) 441 (M + 1, 100).

16  
17  
18  
19  
20  
21  
22  
23 **5-(4''-Cyanoethyl-2'',6''-dimethylphenoxy)-N<sup>1</sup>-(4'-cyanophenyl)-4-hyd**  
24 **roxymethylbenzene-1,2-diamine (15h)**. Starting with 440 mg (1 mmol) of **12h** to  
25 afford 264 mg of **15h**, yield 64%, brown solid, mp 115-117 °C, <sup>1</sup>H NMR  $\delta$  ppm 2.10  
26 (6H, s, 2  $\times$  CH<sub>3</sub>), 2.61 (2H, t,  $J = 7.2$  Hz, CH<sub>2</sub>CN), 2.87 (2H, t,  $J = 7.2$  Hz, ArCH<sub>2</sub>), 4.86  
27 (2H, s, CH<sub>2</sub>O), 5.54 (1H, s, NH), 6.04 (1H, s, ArH-6), 6.55 (2H, d,  $J = 8.8$  Hz,  
28 ArH-2',6'), 6.91 (1H, s, ArH-3), 6.93 (2H, s, ArH-3'',5''), 7.40 (2H, d,  $J = 8.8$  Hz,  
29 ArH-3',5'); MS  $m/z$  (%) 413.4 (M+1, 100); HPLC purity 99.1 %.

30  
31  
32  
33  
34  
35  
36  
37  
38  
39 **5-(4''-Cyanoethyl-2'',6''-dimethyl)phenoxy-N<sup>1</sup>-(4'-cyanophenyl)benze**  
40 **ne-1,2,4-triamine (15i)**. Starting with 100 mg (0.22 mmol) of **12i**, which was reported  
41 previously,<sup>10</sup> to afford 60 mg of **15i**, yield 70%, white solid, mp 118-20 °C, <sup>1</sup>H NMR  $\delta$   
42 ppm 2.11 (6H, s, 2  $\times$  CH<sub>3</sub>), 2.61 (2H, t,  $J = 7.2$  Hz, CH<sub>2</sub>CN), 2.86 (2H, t,  $J = 7.2$  Hz,  
43 CH<sub>2</sub>Ar), 5.36 (1H, s, NH), 5.94 (1H, s, ArH-6), 6.30 (1H, s, ArH-3), 6.48 (2H, d,  $J = 8.8$   
44 Hz, ArH-2',6'), 6.91 (2H, s, ArH-3'', 5''), 7.37 (2H, d,  $J = 8.8$  Hz, ArH-3',5'); MS  $m/z$   
45 (%) 398 (M + 1, 100); HPLC purity 100.0 %.

46  
47  
48  
49  
50  
51  
52  
53  
54 **(E)-1-(4-Cyanophenyl)-6-(4-(2-cyanovinyl)-2,6-dimethylphenoxy)-N-m**  
55 **ethyl-1H-benzo[d]imidazole-5-carboxamide (16a)**. Hydrochloric acid (1N, 0.5  
56  
57  
58  
59  
60

1  
2  
3 mL) was added to a solution of **14f** (20 mg, 0.046 mmol) in triethyl orthoformate (0.1  
4  
5 mL, excess), diethyl ether, and DMF (2 mL) with stirring. The mixture was stirred at rt  
6  
7 for 3 h under a nitrogen atmosphere, poured into water, adjusted to pH 6-7, and stirred  
8  
9 for an additional 15 min. The white solid was collected and washed with water until  
10  
11 neutral to yield 17 mg of **16a** in 85% yield, mp 296-298 °C; <sup>1</sup>H NMR δ ppm 2.18 (6H, s,  
12  
13 2×CH<sub>3</sub>), 3.12 (3H, d, *J* = 4.8 Hz, NCH<sub>3</sub>), 5.88 (1H, d, *J* = 16.8 Hz, =CHCN), 6.43 (1H, s,  
14  
15 ArH-7), 7.27 (2H, s, ArH-3'', 5''), 7.36 (1H, d, *J* = 16.8 Hz, ArCH=), 7.42 (2H, d, *J* = 8.8  
16  
17 Hz, ArH-3', 5'), 7.80 (2H, d, *J* = 8.8 Hz, ArH-2', 6'), 8.09 (1H, s, ArH-4), 8.89 (1H, s,  
18  
19 ArH-2). MS *m/z* (%): 448 (M+1,100). HPLC 96.2%.

22  
23 **6-(4-(2-Cyanoethyl)-2,6-dimethylphenoxy)-1-(4-cyanophenyl)-*N*-meth**  
24  
25 **yl-1*H*-benzo[d]imidazole-5-carboxamide (16b).** The same reaction and conditions  
26  
27 as for the preparation of **16a**. Starting with **15f** (20 mg, 0.046 mmol) with triethyl  
28  
29 orthoformate (0.1 mL, excess) to afford 16.5 mg of **16b**, yield 81%, white solid, mp  
30  
31 300-302 °C; <sup>1</sup>H NMR δ ppm 2.14 (6H, s, 2×CH<sub>3</sub>), 2.68 (2H, t, *J* = 6.8 Hz, CH<sub>2</sub>CN), 2.92  
32  
33 (2H, t, *J* = 6.8 Hz, ArCH<sub>2</sub>), 3.11 (3H, d, *J* = 4.8 Hz, NHCH<sub>3</sub>), 6.47 (1H, s, ArH-7), 7.05  
34  
35 (2H, s, ArH-3'', 5''), 7.40 (2H, d, *J* = 8.8 Hz, ArH-3', 5'), 7.81 (2H, d, *J* = 8.8 Hz,  
36  
37 ArH-2', 6'), 8.09 (1H, s, ArH-4), 8.90 (1H, s, ArH-2); MS *m/z* (%) 450 (M+1,100);  
38  
39 HPLC 100%.

42  
43 **Assessment of Inhibitory Activity on HIV-1 Replication in TZM-bl**  
44  
45 **Cells.** Inhibition of HIV-1 infection was measured as reduction in luciferase gene  
46  
47 expression after a single round of virus infection of TZM-bl cells as described  
48  
49 previously.<sup>17</sup> Briefly, 200 TCID<sub>50</sub> of virus (NL4-3) was used to infect TZM-bl cells in  
50  
51 the presence of various concentrations of compounds. Two days after infection, the  
52  
53 culture medium was removed from each well and 100 μL of Bright Glo reagent  
54  
55 (Promega, Luis Obispo, CA) was added to the cells for measurement of luminescence  
56  
57  
58  
59  
60

1  
2  
3 using a Victor 2 luminometer. The effective concentration ( $EC_{50}$ ) against HIV-1 strains  
4  
5 was defined as the concentration that caused a 50% reduction of luciferase activity  
6  
7 (Relative Light Units) compared to virus control wells.  
8

9  
10 **Assessment of In Vitro Cytotoxicity in TZM-bl Cells.** The in vitro  
11  
12 cytotoxicity of compounds on TZM-bl cells was measured using a colorimetric  
13  
14 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2*H*-tetrazolium-5-carboxanilide (XTT)  
15  
16 assay.<sup>17</sup> Briefly, 100  $\mu$ L of the test compounds at graded concentrations were added to  
17  
18 equal volumes of cells ( $5 \times 10^5$ /mL) in wells of a 96-well plate. After incubation at  
19  
20 37 °C for 4 days, 50  $\mu$ L of XTT solution (1 mg/mL) containing 0.02  $\mu$ M of phenazine  
21  
22 methosulphate (PMS) was added. After 4 h, the absorbance at 450 nm was measured  
23  
24 with an ELISA reader. The CC50 (concentration for 50% cytotoxicity) values were  
25  
26 calculated using the CalsuSyn computer program as described above.  
27  
28  
29  
30

31 **Aqueous Solubility Determination.** Solubility was measured separately at  
32  
33 pH 7.4 and pH 2.0 by using an HPLC-UV method. Test compounds were initially  
34  
35 dissolved in DMSO at 10 mg/mL. Ten microliters of this stock solution was spiked into  
36  
37 either pH 7.4 phosphate buffer (1.0 mL) or 0.01 M HCl (approximately pH 2.0, 1 mL)  
38  
39 with the final DMSO concentration being 1%. The mixture was stirred for 4 h at rt, and  
40  
41 then concentrated at 3000 rpm for 10 min. The saturated supernatants were transferred to  
42  
43 other vials for analysis by HPLC-UV. Each sample was performed in triplicate. For  
44  
45 quantification, a model 1200 HPLC-UV (Agilent) system was used with an Agilent  
46  
47 TC-C18 column ( $250 \times 4.6$  mm, 5  $\mu$ m) and gradient elution of acetonitrile (ACN) in  
48  
49 water, starting with 0% of ACN, which was linearly increased up to 70% over 10 min,  
50  
51 then slowly increased up to 98% over 15 min. The flow rate was 1.0 mL/min and  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 injection volume was 15  $\mu\text{L}$ . Aqueous concentration was determined by comparison of  
5  
6 the peak area of the saturated solution with a standard curve plotted peak area versus  
7  
8 known concentrations, which were prepared by solutions of test compound in ACN at 50  
9  
10  $\mu\text{g/mL}$ , 12.4  $\mu\text{g/mL}$ , 3.125  $\mu\text{g/mL}$ , 0.781  $\mu\text{g/mL}$ , and 0.195  $\mu\text{g/mL}$ .

11  
12 **Log P Measurement.** Using above same DMSO stock solution (10 mg/mL),  
13  
14 20  $\mu\text{L}$  of this solution was added into *n*-octane (1 mL) and water (1 mL). The mixture  
15  
16 was stirred at rt for 24 h and then stood overnight. Each solution (ca. 0.5 mL) was  
17  
18 transferred from two phases respectively into other vials for HPLC analysis. The  
19  
20 instrument and conditions were the same as those for solubility determination. Log P  
21  
22 value was calculated by the peak area ratios in *n*-octane and in water.  
23  
24

25  
26 **Microsomal Stability Assay.** Stock solutions of test compounds (1 mg/mL)  
27  
28 were prepared by dissolving the pure compound in DMSO and stored at 4  $^{\circ}\text{C}$ . Before  
29  
30 assay, the stock solution was diluted with ACN to 0.1 mM concentration. For  
31  
32 measurement of metabolic stability, all compounds were brought to a final concentration  
33  
34 of 1  $\mu\text{M}$  with 0.1 M potassium phosphate buffer at pH 7.4, which contained 0.1 mg/mL  
35  
36 human liver microsomes and 5 mM  $\text{MgCl}_2$ . The incubation volumes were 300  $\mu\text{L}$ , and  
37  
38 reaction temperature was 37  $^{\circ}\text{C}$ . Reactions were started by adding 60  $\mu\text{L}$  of NADPH  
39  
40 (final concentration of 1.0 mM) and quenched by adding 600  $\mu\text{L}$  of ice-cold ACN to stop  
41  
42 the reaction at 5, 15, 30, and 60 min time points. Samples at 0 min time point were  
43  
44 prepared by adding 600  $\mu\text{L}$  ice-cold ACN first, followed by 60  $\mu\text{L}$  NADPH. Incubations  
45  
46 of all samples were conducted in duplicate. After quenching, all samples were  
47  
48 centrifuged at 12,000 rpm for 5 min at 0  $^{\circ}\text{C}$ . The supernatant was collected, and 20  $\mu\text{L}$  of  
49  
50 the supernatant was directly injected onto a Shimadzu LC-MS-2010 system with an  
51  
52 electrospray ionization source (ESI) for further analysis. The following controls were  
53  
54 also conducted: 1) positive control incubation containing liver microsomes, NADPH,  
55  
56  
57  
58  
59  
60

1  
2  
3 and reference compound propranolol; 2) negative control incubation omitting NADPH;  
4  
5 and 3) baseline control containing only liver microsomes and NADPH. The peak heights  
6  
7 of test compounds at different time points were converted to percentage of remaining,  
8  
9 and the peak height values at initial time (0 min) served as 100%. The slope of the linear  
10  
11 regression from log percentage remaining versus incubation time relationships ( $-k$ ) was  
12  
13 used to calculate in vitro half-life ( $t_{1/2}$ ) value by the formula of in vitro  $t_{1/2} = 0.693/k$ ,  
14  
15 regarded as first-order kinetics. Conversion to in vitro  $CL_{int}$  (in units of ml/min/mg  
16  
17 protein) was calculated by the formula<sup>15</sup>:  $CL_{int} = (0.693/in\ vitro\ t_{1/2}) \times (ml\ incubation /$   
18  
19  $mg\ microsomes)$ . The HPLC-MS analysis was carried out on Shimadzu LCMS-2010  
20  
21 with an electrospray ionization source (ESI). An Alltima C18 column (5  $\mu$ m, 150 mm  $\times$   
22  
23 2.1 mm) was used for HPLC with a gradient elution at a flow rate of 0.3 mL/min. The  
24  
25 elution condition was ACN (B) in water (A) at 30% for 0–2 min, 85% for 2–6 min,  
26  
27 100% for 6–9 min, and 30% for 9–12 min. The MS conditions were optimized to  
28  
29 detector voltage +1.6 kV, acquisition mode selected ion monitoring (SIM) of the  
30  
31 appropriate molecular weights of the testing compounds. The CDL and heat block  
32  
33 temperature was 200 °C and neutralizing gas flow was 1.5 L/min. Samples were injected  
34  
35 by auto-sampler. Electrospray ionization was operated in the positive and negative  
36  
37 mode.  
38  
39  
40  
41  
42  
43  
44

## 45 AUTHOR INFORMATION

### 46 Corresponding Author

47  
48  
49  
50 E-mail: [lanxieshi@yahoo.com](mailto:lanxieshi@yahoo.com)

### 51 Notes

52  
53  
54 The authors declare no competing financial interest.  
55  
56  
57  
58  
59  
60

## ACKNOWLEDGMENTS

This investigation was supported by grant 30930106 from the National Natural Science Fund of China (NSFC) awarded to L. Xie and U.S. NIH grants awarded to C. H. Chen (AI65310) and K. H. Lee (AI33066).

## ABBREVIATIONS USED

ACN, acetonitrile; ART, antiretroviral therapy; DAAN, diarylaniline; DAPY, diarylpyrimidine; HAART, highly active antiretroviral therapy; LiBH<sub>4</sub>, lithium borohydride; PMS, phenazine methosulphate; PSA, polar surface area; SPR, structure-property relationship (PMS), XTT, 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide


## References

1. Anthony S. Fauci, AIDS: let science inform policy. *Science* **2011**, 333(6038), 13.
2. Shattock, R. J.; Warren, M.; McCormack, S.; Hankins, C. Turning the tide against HIV. *Science* **2011**, 333(6038), 42-43.
3. Kaufmann, G. R.; Cooper, D. A. Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options. *Curr. Opin. Microbiol.* **2000**, 3, 508-514.
4. Vella, S.; Palmisano, L. Antiretroviral therapy: state of the HAART. *Antiviral Res.* **2000**, 45, 1-7.
5. Pecora Fulco, P.; McNicholl, I. R. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. *Pharmacotherapy* **2009**, 29 (3), 281-294.

6. De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. *Int. J. Antimicrob. Agents* **2009**, 33, 307-320.
7. Sarafianos, S. G.; Marchand, B.; Das, K.; Himmel, D. M.; Parniak, M. A.; Hughes, S. H.; Arnold, E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. *J. Mol. Biol.* **2009**, 385, 693-713.
8. Vingerhoets, J., Azijn, H., Fransen, E.; De Baere, I., Smeulders, L., Jochmans, D., Andries, K., Pauwels, R., de Bethune, M. P. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. *J. Virol.* **2005**, 79, 12773-12782.
9. Qin, B. J.; Jiang, X. K.; Lu, H.; Tian, X. T.; Barbault, F.; Huang, L., Qian, K.; Chen, C. H.; Huang, R.; Jiang, S.; Lee, K. H.; Xie, L. Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors, *J. Med. Chem.* **2010**, 53, 4906-4916.
10. Tian, X. T. ; Qin, B. J.; Wu, Z. Y.; Wang, X. F.; Lu, H.; Morris-Natschke, S. L.; Chen, C. H.; Jiang, S.; Lee, K. H.; Xie, L. Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors, *J. Med. Chem.* **2010**, 53, 8287-8297.
11. De Corte; B. L. From 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk](1,4) benzodiazepin- 2(1H)-one (TIBO) to Etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. *J. Med. Chem.*, **2005**, 48, 1689-1696.
12. Piersanti, G.; Giorgi, L.; Bartoccini, F.; Tarzia, G.; Minetti, P.; Gallo, G., Giorgi, F.; Castorina, M.; Ghirardi, O.; Carminati, P. Synthesis of benzo[1,2-*d*;3,4-*d'*]

- 1  
2  
3  
4 diimidazole and 1*H*-pyrazolo[4,3-*b*]pyridine as putative A<sub>2A</sub> receptor antagonists.  
5  
6 *Org. Biomol. Chem.* **2007**, 5, 2567-2571.  
7  
8  
9 13. Azijn, H.; Tirry, I.; Vingerhoets, de Bethune, J.; M. P.; Kraus, G.; Boven, K.;  
10  
11 Jochmans, D.; Craenenbroeck, E. V.; Picchio, G.; Rimsky, L. T. TMC278, a  
12  
13 next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active  
14  
15 against wild-type and NNRTI-resistant HIV-1. *Antimicro. Agents Chemother.* **2010**,  
16  
17 54, 718–727.  
18  
19  
20  
21 14. Janssen, P. A.; Lewi, P. J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.;  
22  
23 Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Ludovici, D.;  
24  
25 Andries, K.; de Bethune, M. P.; Pauwels, R.; Das, K.; Clark, A. D.; Frenkel, Y. V.;  
26  
27 Hughes, S. H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.;  
28  
29 Williams, P.; Stoffels P. In search of a novel anti-HIV drug: multidisciplinary  
30  
31 coordination in the discovery of  
32  
33 4-[[4-[[4-[(1*E*)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]b  
34  
35 enzonitrile (R278474, Rilpivirine). *J. Med. Chem.* **2005**, 48, 1901-1909.  
36  
37  
38  
39 15. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D.  
40  
41 Molecular properties that influence the oral bioavailability of drug candidates. *J.*  
42  
43 *Med. Chem.* **2002**, 45, 2615–2623.  
44  
45  
46 16. Kerns, E. H. and Di, L. *Drug-like properties: concepts, structure design and*  
47  
48 *methods from ADME to toxicity optimization*. Academic Press, **2008**, pp 65.  
49  
50  
51 17. Dang, Z.; Lai, W.; Qian, K.; Lee, K. H.; Chen, C. H.; Huang, L. Betulinic acid  
52  
53 derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors. *J. Med.*  
54  
55 *Chem.* **2009**, 52, 7887-7891.  
56  
57  
58  
59  
60

## Table of Contents graphic.



## Table of Contents graphic.

